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Introduction: Photo-activated Auger electron therapy is a potential technique that could 
preferentially target cancer cells. This binary therapy uses a drug containing a high-Z element 
like iododeoxyuridine (IUdR), which serves as a radiosensitizer and molecular carrier of high-Z 
iodine into cancer cell DNA. Iodine becomes the Auger electron source when activated by 
photons with an appropriate energy. This work studied the survival of rat 9L glioma cells with 
IUdR replacing thymidine in the DNA. Irradiations at monochromatic energies above and below 
the iodine K-edge (33.2 keV) are part of a larger study from 25-70 keV. It was hypothesized that 
SER10 values for 9% and 18% IUdR-laden 9L glioma cells irradiated by 25-35 keV photons 
would be greatest at 35 keV due to the Auger effect. 
Methods: Rat 9L glioma cells survival versus dose curves with 0%, 9%, and 18% IUdR were 
measured using four irradiation energies (4 MV x-rays; 35, 30, and 25 keV synchrotron 
photons). For each of 11 conditions (Energy, %IUdR) survival curves were fit to the data (826 
cell cultures) using the linear quadratic model. The ratio of doses resulting in 10% survival gave 
sensitization enhancement ratios (SER10) from which contributions due to linear-energy transfer 
(LET), radiosensitization (RS), and Auger effect (AE) were determined. 
Results: At 35, 30, and 25 keV, SER10,LET values were 1.08±0.03, 1.22±0.02, and 1.37±0.02, 
respectively. At 4 MV SER10,RS values for 9% and 18% IUdR were 1.28±0.02 and 1.40±0.02, 
respectively. Assuming LET effects are independent of %IUdR and radiosensitization effects are 
independent of energy, SER10,AE values for 18% IUdR at 35, 30, and 25 keV were 1.35±0.05, 
1.06±0.03, and 0.98±0.03, respectively; values for 9% IUdR at 35 and 25 keV were 1.01±0.04 
and 0.82±0.02, respectively. Contrastingly, a different, more traditional analysis gave SER10,AE 
values of 1.27±0.06 and 1.25±0.06 at 35 keV for 18% and 9% IUdR, respectively. 
xi 
 
Conclusions: Results of this research proved the hypothesis correct; at 35 keV SER10,AE was 
significantly greater than values at 25 and 30 keV for 18% IUdR and at 25 keV for 9% IUdR. 



















CHAPTER 1: INTRODUCTION 
The goal of this project is to elucidate some aspects of photo-activated Auger electron 
therapy, a potential new therapy technique that could preferentially target cancer cells. This is a 
binary therapy that uses a drug containing a high atomic number (Z) element, like iodine in 
iododeoxyuridine (IUdR), for two purposes: (1) as a radiosensitizer and (2) as a molecular carrier 
of a high-Z atom into the DNA of cancer cells. The latter becomes the source of Auger electrons 
when activated by monochromatic photons with an appropriate energy. The current thesis 
describes the survival of rat 9L glioma cells with IUdR incorporated into the DNA (0%, 9%, and 
18% IUdR) irradiated at energies above (35 keV) and below (25, 30 keV) the iodine K-edge. 
This project is part of a larger study intended to span the energy range of 25-70 keV. 
1.1 Current State of the Art in Radiotherapy 
 In current radiotherapy practice, dose is prescribed and delivered to a specified volume of 
tissue called the planning treatment volume (PTV), which includes a mixture of healthy and 
cancerous tissue. The PTV can be accurately irradiated while avoiding nearby normal tissues and 
critical structures by using modern radiation therapy technology such as (1) intensity modulated 
radiotherapy (IMRT), (2) proton and heavy ion therapy, (3) image guided radiotherapy (IGRT), 
(4) motion management (e.g. respiratory gated radiotherapy), and (5) adaptive radiotherapy 
(Zelefsky et al. 2000, Jensen et al. 2011, Verellen et al. 2007, Keall et al. 2002, Keall et al. 
2001). To further improve today’s radiotherapy technology and paradigm, healthy tissue inside 
(and outside) the PTV could be further spared by targeting cancer at the cellular level. One 
potential method for targeting cancer at the cellular level is photo-activated Auger electron 
therapy, a form of chemo-irradiation (combining radiation therapy with drugs that preferentially 




1.2 Photo-Activated Auger Electron Therapy 
 The basis of photo-activated Auger electron therapy utilizes a monochromatic photon 
(i.e., x-ray) with an energy (Eγ) slightly greater than the binding energy (EK) of the K-edge 
electrons of a high-Z atom that is part of the drug attached to the DNA. When a photon interacts 
via the photoelectric effect, a K-shell electron is ejected. Subsequently, orbital electrons cascade 
to fill the vacancy emitting fluorescence photons and Auger electrons (see Figure 1.1). Note that 
fluorescence photons and Auger electrons are competing processes.  
 
Auger electrons, which have a range of approximately 1-400 nm in water (Kassis 2004, 
Kereiakes et al. 1993), deposit a tremendous amount of dose to the surrounding local areas. This 
is illustrated in Figure 1.2(a), where Kassis & Adelstein (2005) used Monte Carlo to simulate the 
emission of Auger electrons from 
125
I decay inside a double-helix DNA. Represented by the 
lines, the Auger electron tracks create multiple nearby ionizations, represented by the “stars.” 
The density of these ionizations is much like that from high-LET  particles, which have a high 
probability for double strand breaks (DSBs) that are difficult to repair (Kassis & Adelstein 
Figure 1.1: Illustration of the Auger effect. A monochromatic photon with Eγ > EK of the atom 
interacts via the photoelectric effect, ejecting a K-shell electron (a). Orbital electrons cascade 




2005). Figure 1.2(b) and (c) are schematic presentations of α, β
-
, and Auger radiation path 
lengths in a cellular and subcellular environment using arbitrary scaling (Buchegger et al. 2006). 
Note that in Figure 1.2(b) the major energy deposition of α and β
-
 radiation occur on tracks of 
40-80 μm and 0.1-10 mm, respectively, while that of Auger electrons (see Figure 1.2(c)) occur in 
the close vicinity of a few nanometers (Buchegger et al. 2006). 
 The scenario depicted in Figure 1.2(a) (caused by radioisotope 
125
I) can also be activated 







(Buchegger et al. 2006). However, the use of radioisotopes for the purpose of triggering Auger 
electrons is outside the scope of this project. Auger electrons can also be triggered by an external 
x-ray beam via photo-activation, interacting with a high-Z atom located in DNA. If a sufficient 
number of high-Z atoms can be incorporated into the DNA of a cancer cell, they can create 
enough Auger events that the damage to the cell due to Auger electrons would be significant. 
Figure 1.2: Simplified illustrations of α, β
-
, and Auger electron radiation deposition. (a) 
Ionization events (represented by “stars”) in double-stranded DNA by α, β
-
, and Auger 
electron radiation. Lines represent particle tracks (Kassis & Adelstein 2005). (b) The range of 
α and β
-
 radiation in cellular environment. (c) The range of Auger electrons in subcellular 
environment. Note that the major energy deposition of Auger electrons occurs in the close 
vicinity of a few nm, while that of α and β
-
 radiation occur on tracks of 40-80 μm and 0.1-10 




 The number of Auger events depends on the high-Z atom, the number of these atoms 
incorporated into the DNA (discussed in Section 1.3.3.1), and the cross section (σ) for the 













), where σ is the cross section (or probability) per unit path length of photon 
interaction, A is the atomic mass of the material, and NA is Avogadro’s number.  The cross 
section depends strongly on the Z of the atoms of the absorbing medium and varies strongly with 
photon energy Eγ.  
1.3 Requirements for High-Z Materials in Photo-Activated Auger Electron Therapy  
 In order for photo-activated Auger electron therapy to be clinically feasible, the high-Z 
material (i.e., drug) must meet four conditions: 
1. It must be close to, attached to, or intercalated with the DNA of the cell; 
2. It should have preferential uptake by cancer cells and in sufficient quantities to elicit a 
therapeutic gain; 
3. The high-Z component of the drug should be equal to or greater than that of iodine (Z ≥ 53) 
to allow sufficient penetration in tissue by photons with Eγ > EK; and 
4. Dose should be delivered using the optimal monochromatic x-ray beam energy to cause as 
many Auger events as possible. 
1.3.1 Cellular Location of IUdR 
 The combining size (i.e., the van der Waals radius) of an atom of iodine is very similar to 
that of a methyl group CH3 (215 pm versus 200 pm, respectively) (Prusoff et al. 1979). The 
halogenated pyrimidine IUdR is a drug that is consequently very similar to the normal DNA 




2006). Since IUdR mimics the van der Waals radius of thymidine, it incorporates into DNA 
during its synthesis (see Figure 1.3). This substitution “weakens” or destabilizes the DNA in the 
cell, making it more susceptible to damage by x-rays (Iliakis & Kurtzman 1989, Hall & Giaccia 
2006), and decreasing the reparability of double strand breaks (Wang & Iliakis 1992).  
 
1.3.2 Selectivity & Quantity of IUdR Uptake 
 IUdR will incorporate preferentially in cells that are proliferating more quickly and thus 
may be expected to sensitize rapidly-growing tumors rather than slowly proliferating normal 
tissue (Karnas et al. 1999). Some examples of rapidly-growing cancer cells are glioblastoma 
multiforme (which arise from astrocytes) and lymphoma (which arise from lymphocytes). 
Mature human brain astrocytes are generally accepted as non-proliferating (Guizzetti et al. 
2011). In contrast, glioblastoma multiforme cells have a doubling time of about 43 hours 
(Coleman et al. 1980). In the case of normal B-cell lymphocytes, they have an estimated cell 
doubling time of 14-21 days, whereas high-grade lymphoma has an estimated doubling time of 
2-3 days (Hong et al. 2009).  
Figure 1.3: Comparison of molecular structure of 
IUdR and thymidine. The circled CH3 of thymidine 
(left) is replaced by I forming the IUdR (right). 





 The quantity of IUdR uptake by the DNA of a cell (thymidine replacement or %IUdR) 
varies with the concentration of IUdR, the amount of time IUdR is exposed to the cells, and the 
type of cells. Since IUdR is taken up by cells only during the S-phase of the cell cycle, IUdR 
must be made available to cells for more than one cell generation (at minimum 1 to 2 population 
doubling times, where 1 doubling time = 1 generation) so that an appreciable quantity of the 
analog may be incorporated into the DNA (Kinsella 1996, Hall & Giaccia 2006). Furthermore, 
since IUdR is rapidly metabolized in both rodent and human cells, continuous exposure, such as 
a prolonged continuous intravenous (c.i.v.) or intra-arterial infusion, is necessary to maximize 
the proportion of tumor cells that incorporate IUdR during S-phase (McGinn & Kinsella 1993). 
 The amount of IUdR uptake can be considerable for certain cell lines in vitro before it 
becomes toxic to the cells (39% thymidine replacement in Chinese hamster lung cells after 24 hr. 
incubation period (Nath et al. 1987); 24% for human D98/AG cells exposed for 5 days (Erikson 
& Szybalski 1963); and 30% for human colon carcinoma cells (HT29) after 4 days of exposure 
(Lawrence et al. 1990)). In vivo, however, IUdR uptake has been considerably less in humans, 
e.g., a maximum of 4.9% after 28 days of c.i.v. infusion (Schulz et al. 2004). The patients that 




, the highest IUdR dosage in the study), 
however, experienced the most significant toxicities of all patients in this trial. This led the 




, which only 
achieved 3% IUdR in vivo. 
 Progress has been made in decreasing the toxicity to in vivo normal tissues by improving 
the drug’s pharmacokinetics. An oral prodrug of IUdR, 5-iodo-2-pyrimidinone-2’-deoxyribose 
(IPdR), efficiently converts to IUdR by the liver enzyme aldehyde oxidase (Chang et al. 1992). 




activity of IPdR aldehyde oxidase (Chang et al. 1992). This study resulted in extensive pre-
clinical testing where oral administration of IPdR has been shown to improve the therapeutic 
index (i.e., lessen toxicity) when compared with c.i.v. IUdR using several different human tumor 
xenograft models (Kinsella et al. 1994, Kinsella et al. 1998, Kinsella et al. 2000a, Seo et al. 
2004, Seo et al. 2005). In addition, systemic toxicology and pharmacokinetics studies on rodent 
and non-rodent animals demonstrated that the MTD of oral IPdR is considerably greater than the 
MTD of IUdR, with little to no significant toxicity (Kinsella et al. 1994, Kinsella et al. 2000a, 
Kinsella et al. 2000b, Kinsella et al. 2008). The first in-human phase 0 trial of IPdR in patients 
with various advanced malignancies resulted in no drug-related adverse events (Kummar et al. 
2013). 
1.3.3 Optimal Monochromatic Energy & High-Z Atom for Production of Auger Events  
1.3.3.1 K-Edge Energy of Iodine & the Production of Photoelectric Events 
 As mentioned in Section 1.2, the high Z-atom, the number of these atoms incorporated 
into the DNA, and the cross section (σ) for the photoelectric interaction of the high-Z atom 
dictates the possible number of Auger events that can occur. Figure 1.4 plots the photoelectric 




33.2 keV (EK, the binding energy for the iodine K-shell) is due to the photoelectric contribution 
of the innermost, K-shell electrons. Below this energy, these electrons do not contribute to 
photoelectric absorption because there is insufficient energy to eject them from the atom. The 
discontinuity in the energy dependence of 
 
 
 is known as the K-edge; its energy is approximately 
proportional to Z
2
. At lower photon energies, the photoelectric absorption edge due to L-edge 




 In regards to clinical applications, the half-value layer (HVL) in tissue of the activating 
photon beam is of therapeutic consequence, as low values might impede access to cancer cells at 
depth (Fairchild et al. 1982). For Z = 53-79 (iodine to gold), K-shell energies range from EK = 
33.2-80.7 keV (Kaye & Laby 1995), which result in HVL in water (approximately tissue) values 
(HVLwater) of ≈ 3.4-6.3 cm (note that HVLwater ≈ 3.6 cm for 35 keV) for broad beam geometry 
(NCRP 2005) and 2.1-3.8 cm for narrow beam geometry (Hubbell & Seltzer 2004). In the case 
of L-edge electrons, energies are so low for Z = 53-79 (EL = 4.6-11.9 keV (Kaye & Laby 1995) 
result in HVLwater ≈ 0.77-1.4 cm for broad beam geometry (NCRP 2005) and 0.013-0.23 cm for 
EL = 4.6 keV 
EK = 33.2 keV 
Figure 1.4: Plot of photoelectric mass attenuation 
coefficients (μ/ρ) for iodine (Z=53) versus photon 
energy for narrow beam geometry. The L- and K-edge 




narrow beam geometry (Hubbell & Seltzer 2004)) that the activating photon cannot penetrate to 
any useful depth in the body.  
 Corde et al. (2004) argued that an irradiation energy of 50 keV would achieve the 
maximum therapeutic effect of IUdR. They used the concept of “dose enhancement ratio” 
(DER), defined as the ratio of the mass energy-absorption coefficient of water in the presence of 
iodine to that in the absence of iodine, i.e.,: 
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is the mass energy absorption coefficient for water, iodine, and a mixture of water 
and iodine irradiated with monochromatic x-ray beam energy, E, and wI is the fraction by weight 
of iodine in the mixture. Figure 1.5 illustrates the energy dependence of the theoretical DER of 
aqueous iodine as a curve having its maximum around 50 keV. The range of energies yielding 
Figure 1.5: Energy dependence of the theoretical DER for several 
iodine aqueous mixtures. From bottom to top, the mass 





such a sharp variation is relatively narrow, from the K-edge of iodine (33.2 keV) up to about 80 
keV.  
1.3.3.2 Toxicity of High-Z Drugs Containing Platinum versus Iodine 
 The toxicity of the high-Z drug chosen for a study of this nature limits the amount of the 
drug that can be incorporated into the cells, thus, influencing the number of Auger events 
possible. Corde et al. (2002) studied the incorporation of cis-diamminedichloroplatinum 
molecules (CDDP) into cells. CDDP, a platinum-containing compound, is a DNA alkylating-like 
molecule (Reed 1992) that, once inside cells, becomes intracellularly activated via the aquation 
process (i.e., a chloride group is displaced by water). CDDP covalently bonds to DNA, 
preferentially binding to guanine-rich portions of DNA (Reed 1992), and forms DNA adducts 
that causes cytotoxicity by way of apoptosis (Ferri et al. 2013). Figure 1.6 summarizes Corde’s 
et al. (2002) findings, which illustrates the survival curves for SQ20B cells exposed to 1 μM 
CDDP for 12 hours prior to being irradiated with photon energies above (78.8 keV; closed 
triangle) or below (78.0 keV; open triangle) the K-shell absorption edge of platinum (78.4 keV). 
Control cells (closed circles) were incubated in platinum-free medium. No difference was found 
in the survival fraction versus dose when the cells were irradiated with beams above and below 
the platinum K-edge, as shown in Figure 1.6. However, the higher cell death resulting from drug 
toxicity limited the uptake (e.g., 1 μM CDDP exposure for 12 hours resulted in 17% cell survival 
(83% cell killing) as shown in Table 1.1).  
Conversely, Figure 1.7 demonstrates the radiobiological response of V79 cells containing 
16% IUdR irradiated with photons just below (32.9 keV; diamonds) or above (33.4 keV; 




                                  
 
at both 32.9 keV and 33.4 keV for cells containing 16% IUdR. Unlike CDDP-loaded cells, which 
suffered a decrease in cell survival from 100% for control cells to 17% for cells treated with 1 
Figure 1.6: Survival curves for SQ20B 
cells with CDDP. Cells were exposed to 
1 μM CDDP for 12 h and irradiated 
above (closed triangle) or below (open 
triangle) the K-shell absorption edge of 
platinum (78.4 keV). Control cells 
(closed circles) were incubated in 
platinum-free medium (Corde et al. 
2002). 
CDDP exposure Survival (%) Platinum content
(atoms/cells)
0.1 μM for 48 h 66 7.0 x 104
3 μM for 6 h 25 4.0 x 106
1 μM for 12 h 17 4.5 x 106
10 μM for 6 h 0.8 7.5 x 106
3 μM for 12 h 0.4 9.0 x 106
Table 1.1: Correlation between the toxicity of several CDDP 
exposures to SQ20B cells and the intracellular platinum content 




μM due to drug toxicity (Corde et al. 2002), Laster et al. (1993) reported a cell survival of 69% ± 
8% for 6 μM IUdR-treated cells (corresponding to 16% IUdR) before cell irradiations.  
The difference in the survival of cells containing either CDDP or IUdR can be explained 
simply by the fact that insufficient CDDP was incorporated into the DNA of cells before toxicity 
occurred to elicit a therapeutic gain in cell death due to the Auger effect. Despite Corde and 
colleagues (2002) confirming the nuclear localization of platinum, higher levels (> 1 μM) of 
platinum atoms in the DNA were strongly limited by the toxicity of the CDDP. Consequently, 
higher intranuclear platinum contents could not be achieved under their experimental conditions.  
Figure 1.7: Irradiated Chinese hamster V79 cells 
with and without IUdR (16.3% thymidine 
replacement). Cells were irradiated with energies 
just above (33.4 keV; triangles; D10 = 2.7 Gy) 
and below (32.9 keV; diamonds; D10 = 3.4 Gy) 
the iodine K-edge to see if any additional 
biological damage would accrue from Auger 
events. Circles represent control cells (D10 = 7.5 
Gy). A therapeutic gain of about 3 was achieved 
for cells irradiated above the K-edge, i.e., 
including both sensitization and the Auger effect 





 Despite Corde’s et al. (2002) findings, Rosseau et al. (2007) further investigated 
platinum-containing drugs by using carboplatin in the treatment of tumors. Not surprisingly, the 
average survival time of glioma-bearing rats following intracerebral delivery of carboplatin and 
photon irradiations was the same as photon irradiation alone, i.e., there was no therapeutic gain 
from photo-activation evident. 
1.3.3.3 Number of Auger Events in DNA per Dose in Water 
The high-Z drug chosen for a study of this nature, the amount incorporated into the DNA, 
and the irradiating photon energy determine the average number of photoelectric events per cell 
nucleus per dose in water. A theoretical estimate (based on the photoelectric cross section) of the 
number of photoelectric events per cell per 2 Gy dose for cells containing 1 μM CDDP (83% 
toxicity) is 0.1 (Corde et al. 2002) as opposed to 13.0 for cells containing 20% IUdR (30% 
toxicity; see Table 1.2). The derivation of this estimate can be found in Appendix A. 
 Similar theoretical calculations by Humm and Charlton (1989) for IUdR showed the 
number of K-shell photoelectric events in iodine atoms per 2 Gy dose in the DNA of a single cell 
assuming a 20% IUdR substitution in DNA (see Table 1.3). They calculated 11.8 and 5.2 
photoelectric events per 2 Gy for 33.2 keV and 60 keV, respectively.  
Table 1.2: The number of Auger events per 2 Gy dose to water. Cells contained either CDDP 
(4.5 x 10
6
 atoms/cell) or IUdR (6.0 x 10
8
 atoms/cell; 20% thymidine replacement) in the DNA. 
Note that only K-edge interactions were considered. 
Drug High-Z Eγ σPE # Atoms per Toxicity # Auger events per cell
& Quantity Atom (keV) (barns) cell in DNA (%) per 2 Gy dose to water
1 μM CDDP Platinum 78.4 2,909 4.5 x 10
6
83 0.1






  According to theoretical calculations by Karnas et al. (2001), photoelectric event 
predictions are higher at these energies when interactions from all orbital shells (K-, L-, M-,..) 
are considered. According to their results, there would be 20.76 and 8.92 photoelectric events 
(67.6% from K-shell, 21.1% from L-shell, and 11.3% from M-, N-, and O-shell interactions), in 
iodine atoms per 2 Gy dose for cells containing 20% IUdR irradiated at 33.2 and 60 keV, 
respectively (see Table 1.4). The number of photoelectric interactions within iodine is largest at 
the K-edge energy of iodine.  
1.3.3.4 Number of DSBs in DNA per Dose in Water  
Of the number of photoelectric interactions (Auger events) possible, a proportion 
produces DSBs in the DNA of the cell. There is an estimated occurrence of 60-72 DSBs per 2 
Gy delivered to water for cells with no IUdR (Karnas et al. 2001, Heilmann et al. 1995, Humm 
& Charlton 1989). An additional amount of DSBs would occur if the cells were IUdR-loaded. 
Karnas et al. (2001) predicted and experimentally measured the number of DSBs formed per Gy 
for cells containing 20% IUdR. Through Monte Carlo techniques, of the estimated 11.82 
photoelectric events per 2 Gy that can occur for IUdR-laden cells irradiated with tungsten-
filtered 100 kVp x-rays, 3.30 DSBs were predicted to occur (see Table 1.4). By comparison, they 
Table 1.3: The number of photoelectric interactions 
in iodine per 2 Gy for different photon energies 
with 20% IUdR incorporation into the DNA 
(Humm & Charlton 1989). 
Photon Photons/ Cross Section # Auger events
Energy cm2 * Gy cm2/atom per 2 Gy
33.2 keV 1.49 x 1012 7.41 x 10-21 11.8
60 keV 3.30 x 1012 1.51 x 10-21 5.2




found that 7.2 ± 3.2 DSBs per 2 Gy occurred when measured using comet assays. They attribute 
the higher measured levels of DSBs to be a result of DNA damage from Auger electrons 
spanning across giant loop structures of DNA, something that the Monte Carlo simulation did 
not account for. Because these theoretical calculations are based on macro-dosimetry, Karnas 
and colleagues believe that DSBs from Auger events may be more complex due to the 
unaccounted micro-dosimetry. 
 Both the number of photoelectric events and number of DSBs at 33.2 keV are 
approximately double of that at 100 kVp (tungsten-filtered). The largest number of photoelectric 
events predicted by Karnas et al. (2001) was 20.76 per 2 Gy at 33.2 keV, of which 5.82 were 
predicted to form DSBs.  
Energy # of photoelectric Predicted # of DSBs
(keV) events in any shell formed per 2 Gy









30 kVp 7.48 1.72
100 kVp 7.34 1.94
W-filtered 11.82 3.30
100 kVp
Table 1.4: The production of electron orbital 
vacancies from photoelectric events in iodine.  
Assuming a 20% IUdR substitution in DNA, the 
corresponding calculated DSB production from 
Auger events as a function of energy are also 




1.4 Suitability of IUdR in Photo-Activated Auger Electron Therapy 
IUdR has been recognized as a radiosensitizer (using ionizing radiation) to mammalian 
cells since the 1960’s (Djordjevic & Szybalski 1960, Miller et al. 1987, Kinsella 2008). The 
mechanism for radiosensitivity by IUdR is believed to be the release of the halogen by free 
radical attack resulting in a free uracil radical. Instability in the DNA backbone is then induced 
through abstraction of a hydrogen atom from the deoxyribose of DNA (Prusoff et al. 1979). In 
addition to being a radiosensitizer, IUdR is the vehicle in which iodine is incorporated into DNA, 
where it becomes the activator of Auger electrons when irradiated with photons of an appropriate 
energy (Laster et al. 1993).  
 IUdR is suitable for photo-activated Auger electron therapy because (1) of its ability to 
incorporate into DNA by substituting the base pair thymidine during S-phase of the cell cycle 
(see Section 1.3.1), (2) the selectivity of rapidly dividing cells and sufficient quantity that 
incorporates into DNA makes it possible for IUdR to target fast growing tumors, (3) iodine 
produces photoelectric events when irradiated with the optimal photon energy that translate to 
Auger electrons and ultimately DSBs (with acceptable toxicity) (see Sections 1.3.2 and 1.3.3), 
and (4) for the high-Z atom iodine, the energy at which photo-activated Auger electrons are 
released (EK = 33.2 keV) is just sufficiently high to penetrate a useful depth in the body 
(HVLwater ≈ 3.4 cm for broad beam geometry) (see Section 1.3.3.1). Utilizing IUdR in photo-
activated Auger electron therapy on patients with high-grade brain tumors could potentially 
minimize problems associated with radiosensitization of normal tissues since these rapidly 
proliferating (potential tumor doubling times of 5 to 15 days) radioresistant tumors are 
surrounded by non-proliferating normal brain tissues that show little to no DNA incorporation of 




1.5 Pre-Clinical & Clinical Studies with IUdR 
1.5.1 Conventional X-Ray Energy Irradiations with IUdR 
X-rays from sources such as 
137
Cs (662 keV), 
60
Co (1.17 and 1.33 MeV), and clinical 
linear accelerator energies of 4-15 MV induce a response in tissue that is primarily from 
Compton scattering (i.e., no photoelectric interactions releasing Auger electrons), so the effects 
of radiosensitization alone in IUdR can be studied. In this energy range (low linear-energy 
transfer (LET)), IUdR has been shown as an effective in vitro radiosensitizer with sensitization 
enhancement ratios at the 10% survival level (SER10; discussed in Section 4.2.4) that are 
dependent on cell line, ranging from 1.8-2.6 (Fairchild et al. 1985, Miller et al. 1987, Nath et al. 
1987, Shinohara et al. 1996, Dugas et al. 2011) (see Table 1.5). 
 Results from small animal investigations using various IUdR infusion schemes have been 
promising. Deutsch et al. (1990) showed improved median survival of rats with brain 
gliosarcoma after receiving 24 Gy in three fractions with IUdR + 4 MV x-rays (30.5 days), as 
compared to IUdR (21.5 days) or 4 MV x-rays (19.5 days) alone. Harrington et al. (2004) 
showed improvement in the volume tripling time of KB xenographs in mice receiving 15 Gy in 
five fractions using an encapsulated IUdR called pegylated liposomal IUdR (PLIUdR) + 
137
Cs x-
Table 1.5: SER10 values for CHO, V79, and HeLa cells containing similar 
amounts of IUdR. Cells were irradiated with either 
137
Cs (662 keV), 
60
Co 
(1.17 and 1.33 MeV), 4 MV, or 15 MV x-rays. Irradiations at these energies 
induce primarily Compton interactions (i.e., no photon activation), so the 
effects of radiosensitization alone in IUdR can be studied. 
Energy %IUdR IUdR Exposure SER10 Cell Line Reference
Time
Cs-137 20% 12 hrs 2.0 V79 Fairchild et al. 1985
Co-60 20% 18 hrs 1.8 HeLa Shinohara et al. 1996
4 MV 18.1% 3 days 2.2 CHO Nath et al. 1987
4 MV 16.6 ± 1.9% 27 hrs 2.6 CHO Dugas et al. 2011




rays (34 days), as compared to PLIUdR (9 days) or 
137
Cs x-rays (19 days) alone. Combinations 
of conventional radiation with the less toxic prodrug IPdR have been found to significantly 
inhibit growth of human colorectal and glioblastoma xenografts over inhibition due to radiation 
alone (Kinsella et al. 2000a, Kinsella et al. 2007). 
 In clinical trials, however, IUdR failed to exhibit significant radiosensitization in early 
studies because normal tissue toxicity limited uptake into the tumor. For example, Schulz et al. 
(2004) showed maximum uptakes of 4.9% IUdR in granulocytes of human malignant glioma 
patients, but also exhibited significant toxicities (see Section 1.3.2). In other clinical trials, such 
as that reported by Epstein et al. (1992), tumor responses were mixed. Recently, though, there is 
promising research with the oral prodrug IPdR due to more favorable pharmacokinetics leading 
to the first human phase 0 trial (Kummar et al. 2013) (discussed in Section 1.3.2). It is likely that 
human clinical trials with radiation therapy will follow in the near future. 
1.5.2 Monochromatic X-Ray Energy Irradiations with IUdR 
 Knowing how to best use monochromatic x-rays to increase the local dose to DNA from 
Auger electrons (see Section 1.3.3) is important for the clinical success of photo-activated Auger 
electron therapy with IUdR. Work done by Laster et al. (1993) (discussed in Section 1.3.3.2) 
studied the use of IUdR and the biologic efficacy of Auger electrons when monochromatic 
photons were used to photo-activate IUdR in vitro. Using V79 cells with 16% IUdR, they 
reported that IUdR had a SER10 value of 3.0 ± 0.2 for 33.4 keV photons. Also, 33.4 keV photons 
were found to be a factor of 1.4 more effective than 32.9 keV photons in damaging iodinated 
cells (see Figure 1.7 in Section 1.3.3.2). They also reported a SER10 value of 2.0 for 
137
Cs 
irradiation (see Table 1.5). Hence, the therapeutic gain in SER10 from Auger electrons was 




without IUdR (18% IUdR) for 250 kVp and 4 MV x-rays, and the results showed SER10 values 
of 3.2 and 2.2, respectively. This indicates a therapeutic gain in SER10 as a result of Auger 
electrons to be 1.5 (3.2/2.2). Karnas et al. (1999) studied the survival of CHO cells with and 
without IUdR (18% IUdR) for three different polychromatic x-ray beams, and their data showed 
SER10 to be greatest (3.0) for their tungsten-filtered 100 kVp x-ray beam.  
 Dugas et al. (2011) investigated in vitro the dependence of CHO cell survival on 
thymidine replacement levels of 9.2%, 12.0%, and 16.6% using 35 keV monochromatic photons. 
Figure 1.8(a) plots surviving fraction ( 1) versus dose to water, with the upper curve showing 
data for CHO cells without IUdR irradiated by either 4 MV x-rays or 35 keV photon beams, for 
which there was no significant difference in the survival curve, and the lower curve showing data 
for CHO cells with IUdR replacing 16.6% thymidine irradiated by the 4 MV x-ray beam. The 
solid line represents the fit to the linear quadratic (survival) model. Based on fits to the linear 
quadratic model, the SER10 value was 2.6. This demonstrates the temporary ability of IUdR to 
compromise DNA repair (i.e., radiosensitization effect). Figure 1.8(b) compares the results from 
Figure 1.8(a) to data for CHO cells irradiated at 35 keV. Based on the fit to the linear quadratic 
model, the SER10 value for the (4 MV & 35 keV, 0% IUdR) versus (35 keV, 16.6% IUdR) data 
was 4.1. This is due to the combined effects of radiosensitization and Auger events. Compared to 
a SER10 value of 2.6 for the (4 MV & 35 keV, 0% IUdR) versus (4 MV, 16.6% IUdR) data, the 
Auger effect resulted in a therapeutic gain of 1.6 (4.1/2.6).  
 Looking at lower IUdR concentrations, Figure 1.9(a) and (b) show results for CHO cells 
with or without 12.0% and 9.2% IUdR and irradiated at 4 MV or 35 keV. Comparing Figure 
1.8(b) to Figure 1.9(a), the SER10 values are reduced from 4.1 to 3.0 for 35 keV and from 2.6 to 




to 1.4. Comparing Figure 1.8(b) to Figure 1.9(b), the SER10 value is reduced to 2.0 for 35 keV 
and to 1.5 for 4 MV x-rays. This corresponds to a decrease in the SER10 to 1.3 for 9.2% IUdR as 
a result of the Auger effect.  
Figure 1.8: CHO cells with 16.6% IUdR irradiated at 
4 MV or 35 keV. (a) Cells with IUdR irradiated at 4 
MV compared to cells without IUdR irradiated at 
either 4 MV or 35 keV. A SER10 value of 2.6 is 
observed for cells irradiated at 4 MV due to the 
radiosensitization effect of IUdR. (b) Cells irradiated 
at 35 keV. A SER10 of 4.1 is observed due to the 
radiosensitizing effect of IUdR and the Auger effect 






From these results, Dugas and colleagues concluded that SER10 values for both 4 MV and 
35 keV x-rays increased monotonically with increasing %IUdR from 9.2% to 16.6%. At each 
%IUdR level, the therapeutic gain was greater for 35 keV than for 4 MV, although the benefit 
Figure 1.9: CHO cells with 12.0% and 9.2% IUdR 
irradiated at 4 MV and 35 keV. (a) Cells with or 
without 12.0% IUdR irradiated at 4 MV and 35 
keV. A SER10 of 3.0 is observed due to the 
radiosensitizing effect of IUdR and Auger effect. (b) 
Cells with or without 9.2% IUdR irradiated at 4 MV 
and 35 keV. A SER
10
 of 2.0 is observed due to the 
radiosensitizing effect of IUdR and Auger effect 






from radiosensitization due to IUdR was greater than that from Auger electrons contributing 
additional dose to the DNA using 35 keV. Even though the Auger effectiveness was less than the 
radiosensitization factor of IUdR, the authors believed that both effects could be important for 
the clinical efficacy of IUdR radiotherapy.  
 For in vitro SQ20B human cells (estimated 10-20% IUdR) Corde et al. (2004) showed 
survival curves with SER10 values of 1.25, 1.64, 2.60, and 1.45 at photon beam energies of 32.8, 
33.5, 50, and 70 keV, respectively, (see Figure 1.10). Their greatest SER10 value (2.60) occurred 
at 50 keV, consistent with the theoretical DER peak (see Figure 1.5 in Section 1.3.3.1). In 
contrast to the optimal energy reported by Corde et al.(2004), Rousseau et al. (2009) showed no 
significant differences in median survival of rats with F98 glioma that received 15 Gy in one 
fraction when using IUdR + 50 keV photons (46 days) and 50 keV photons alone (44 days). 
  
Figure 1.10: Survival curves for SQ20B cells. Cell were irradiated with (open symbols) or 
without (closed symbols) 10 μM IUdR for the energies (a) below the iodine K-edge (32.8 keV; 
triangles) and above the iodine K-edge (33.5 keV; reversed triangles), (b) 50 keV (squares), and 




 Corde’s et al. (2004) data for Eγ (= 32.8 keV) < EK in Figure 1.10(a) is unusual. First, 
there is no shoulder in the survival curves for cells irradiated without IUdR, a prominent feature 
in survival curves of cells with no radiosensitizing agent. Second, the ratio of SER10 values 
above and below the K-edge was 1.33, somewhat lower than values ranging from 1.4-1.6 
reported by others in this section. Third, the data presented in Corde et al. (2004) is also limited 
in that only two energies above 33.5 keV were explored. As of this writing, however, it is the 
only published data with energies well above the K- edge of iodine.  
 Recent studies by the LSU-MBPCC research group have aimed at understanding the 
dependence of the Auger effect on cell survival as a fraction of % thymidine replacement by 
IUdR (%IUdR) and photon energy, Eγ. The former has been studied at 35 keV by Dugas et al. 
(2011), and current studies by this group are investigating the latter over the energy range 25-70 
keV, as the Corde et al. (2004) data has too many inconsistencies and too few energy data points 
to discern between observed SER10 values being related to the DER or the number of Auger 
events per unit dose. The present study has looked at data in the range of 25-35 keV.  
1.6 Purpose, Hypothesis, & Aims 
Because the potential for photo-activated Auger electron therapy cannot be realized until 
there is a better understanding of basic mechanisms, this project aims to understand the 
biological effect of 9% and 18% IUdR incorporated into rat 9L glioma cells as a function of 
photon energy (25-35 keV).  
 Hypothesis: It was postulated that the SER10 value for 9% and 18% IUdR-laden rat 9L 
glioma cells irradiated by 25-35 keV photons will be greatest at 35 keV due to the Auger 
effect. 




 Aim 1, IUdR Incorporation: Rat 9L glioma cells will be grown with IUdR replacing 9% and 
18% thymidine in the DNA. 
 Aim 2, Cell Survival Measurements: Survival curves for 9L glioma cells with 0%, 9%, and 
18% thymidine replacement will be measured with 4 MV x-rays and 25-35 keV photon 
beams. 
 Aim 3, Data Analysis: A survival curve will be fit to data for each combination of % 
thymidine replacement and photon beam energy using a linear quadratic model for surviving 





CHAPTER 2: AIM 1, IUDR INCORPORATION 
Aim 1: Rat 9L glioma cells will be grown with IUdR replacing 9% and 18% of thymidine in the 
DNA. 
2.1 Goal 
The goal of this aim is to determine the appropriate concentration of IUdR required in 
growth medium such that 9% or 18% of thymidine is replaced by IUdR in the DNA of 9L glioma 
cells during cell synthesis. This will allow cell survival measurements of 9L cells with 0%, 9%, 
and 18% IUdR thymidine replacement using 25 keV, 30 keV, 35 keV, and 4 MV x-rays. 
2.2 Materials & Methods 
2.2.1 Cell Line 
Rat 9L glioma cells, supplied by C. J. Koch, Ph.D. (Evans et al. 1995), of the University 
of Pennsylvania, were chosen for this study from other available cell lines because 9L cells are 
radioresistant and will grow both in vitro and in vivo (Leith et al. 1975, Weizsaecker et al. 1981) 
(the possibility of implantation into syngeneic rats for in vivo animal studies is important for 
future work). 9L cells reflect the situation encountered clinically with human gliomas where 
radiotherapy has been ineffective in producing cures.  
 Two additional characteristics make 9L cells a good cell line for the present study. First, 
the number of cells that survive plating from generation to generation (i.e., the plating efficiency) 
is 45% ± 15%, making it easy to count the number of cells required to be plated for maintenance 
of cells and experiments. Second, they have a doubling time of approximately 16 hours, as 
preliminary measurements in this study indicated, which keeps the time required to wait for cells 
to proliferate within a manageable range.  




 Cells were maintained in log-phase growth and were grown in Debulcco’s Modified 
Eagle Medium (Gibco®, Life Technologies Corp., Grand Island, NY) supplemented with 10% 
fetal bovine serum (Hyclone®, Thermo Fisher Scientific, Inc., Logan, UT), 20 mM Hepes (N-(2-
hydroxyethyl)piperazine-N’-2-ethanesulfonic acid) buffer, and approximately 0.5% V/V 
penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO). The cells were maintained at 37
o
C 
inside a water-jacketed incubator with humidified air containing 5% CO2 (i.e., standard 
conditions) in the tissue culture facility at the LSU Pennington Biomedical Research Center 
(PBRC). Cells were tested and confirmed free of mycoplasmal contamination using a kit 
purchased from Bionique® Testing Laboratories, Inc. (Saranac Lake, NY). 
2.2.2 IUdR Uptake Studies 
A modified method from Miller et al. (1987), as described in Dugas et al. (2011), was 
used to determine the percentage of IUdR incorporated into the DNA of 9L cells. Cell culture 
flasks containing approximately 2 x 10
5
 cells were prepared. Radiolabeled IUdR was added the 




I-IUdR (Perkin-Elmer, Inc., 
Billerica, MA) and either 1 or 3 μM non-radiolabeled IUdR was added to the cell culture flasks. 
Two 200 μL aliquots were immediately removed from each cell culture flask, before any DNA 
incorporation could occur, and stored in a refrigerator for determining the activity of the medium 
overlay. The activity of the medium was used to correct for radioactive decay occurring between 
the times of radiolabeling of the cells and reading the activity levels of all the cell cultures.  
 The cell cultures were allowed to incubate for 27 hours at standard conditions to allow at 
least one doubling time (i.e., one generation of daughter cells) for uptake and incorporation of 
the radiolabeled IUdR into their DNA. After the incubation period, the overlay medium was 




Hank’s balanced salt solution to eliminate any remaining residual medium. The DNA of each 
cell culture was then extracted, purified, precipitated, and rehydrated using a Wizard Genomic 
DNA Purification Kit (Promega Corp., Madison, WI) using the protocol outlined in Appendix B.  
 The extracted DNA of each cell culture was rehydrated using 250 μL of rehydration 
solution. A 200 μL aliquot of the resulting DNA solution was used for assaying radioactivity in 
the form of counts per minute (cpm). The counts per minute for each 200 μL aliquot of 
rehydrated DNA solution (cpmDNA), and both reserved 200 μL aliquots of the medium overlay 
(cpmoverlay), were read twice consecutively using a Cobra II Auto-Gamma Counter (Packard 
Instrument Co., Inc., Meriden, CT). Each reading was corrected for background by subtracting 
the background counts per minute (i.e., counter reading with sample removed). The multiple 
readings per aliquot were averaged to get a single cpm reading.  
 The following equation, derived from the equations used to calculate % thymidine 
replacement in Dugas et al. (2011), was used to calculate the %IUdR for each rehydrated DNA 
solution: 
 
        
                           
                    
       
(2.1) 
where: 
 cpmDNA = Counts per minute for the 200 μL rehydrated DNA solution (cpm), 
 MWDNA = Molecular weight of two base pairs (1 adenine + 1 thymidine + 1 cytosine +  





 CIUdR = Molar concentration of IUdR initially added to medium overlay (M = mol*L
-1
), 
 Voverlay = Volume of medium overlay aliquot = 2 x 10
-4
 L, 
 cpmoverlay = Counts per minute for the 200 μL medium overlay aliquot (cpm), 




  where  ε = Extinction coefficient for DNA = 0.05 g*L
-1
, 
A260nm = Measurement of absorbance of rehydrated DNA solution at  
 260 nm (unitless), 
 VDNA = Volume of rehydrated DNA solution (200 μL) + 400 μL rehydration 
 solution = 6 x 10
-4
 L. 
 To calculate the concentration of DNA in the solution, the 200 μL aliquots of rehydrated 
DNA solution used to measure cpmDNA were diluted with an additional 400 μL of rehydration 
solution and transferred into a quartz cuvette for measurement of the absorbance at 260 nm 
(A260nm) and 280 nm (A280nm) using a Genesys 10 UV Spectrophotometer (Thermo Fisher 
Scientific, Inc., Waltham, MA). The spectrophotometer exposed each DNA solution to 
ultraviolet light (260 nm wavelength), and a photon detector measured the light that passed 
through the DNA solution. Using the Beer-Lambert law, the amount of light absorbed by the 
DNA solution was related to the concentration of the absorbing molecule. At a wavelength of 
260 nm, the average extinction coefficient for double-stranded DNA is 50 μg*mL
-1
.  
 The ratio of the absorbances at 260 nm and 280 nm (A260/280) was used to assess the 
purity of the DNA solution for quality assurance. Pure DNA has an A260/280 > 1.75, and in 
practice, A260/280 = 1.75-1.96. Therefore, samples with A260/280 < 1.75 were considered 
contaminated and were discarded. 
 For calculation purposes, one molecule of DNA was taken to be two base pairs (1 
adenine + 1 thymidine + 1 cytosine + 1 guanine). By this definition, the molecular weight of one 
mole of DNA (i.e., 2 base pairs) is 1.29 x 10
3
 g (Dugas et al. 2011). Following this logic, when 
calculating the %IUdR in a DNA solution, the number of molecules of thymidine equals the 




2.2.3 Data Acquisition & Analysis 
 IUdR concentrations between 1 and 5 μM were selected for generating the relationship 
between IUdR and thymidine replacement. Three to four experiments were conducted for each 
concentration of 1, 2, 3, and 5 μM IUdR. For experiments at each concentration, 2-3 cell culture 
flasks were used with each cell culture flask resulting in one data point. All data points were 
aggregated for each concentration (9-12 data points per concentration), making up a data set for a 
particular concentration, and the mean % thymidine replacement was computed. Data points 
were tested for outliers using Chauvenet’s criterion (Bevington 1992). If any data points for a 
particular IUdR concentration were considered outliers, they were removed from the data set, 
and the mean thymidine replacement was re-calculated. The mean thymidine replacement was 
then plotted against IUdR concentration and fitted using a weighted least squares fit from which 
reduced-chi squared was calculated. The standard error of the mean (SEM) was used as the 
uncertainty in the mean thymidine replacement data. 
2.3 Results & Discussion 
Based on previous CHO cell data from Dugas et al. (2011), initial IUdR uptake studies 
were done with various concentrations of IUdR (2-20 μM) in multiple trials to determine what 
concentration yielded the targeted 9% and 18% replacement. It was found, however, that rat 9L 
glioma cells take up IUdR more readily than CHO cells (see Table 2.1). For example, incubating 
cells with 5 μM IUdR for a 27-hour period resulted in 26.4% thymidine replacement in 9L cells 
as opposed to 9.2% in CHO cells.  
There are two possible explanations for the differences in uptake efficiency between 9L 




each cell line. The recommended medium for CHO cells is Ham's F-12 nutrient mix (Gibco®, 
Life Technologies Corp., Grand Island, NY), which contains 2.89 μM thymidine, as quoted from 
the company’s website. The Dulbecco's Modified Minimal Essential Medium used for rat 9L 
glioma cells contained no thymidine. It is possible that in the chemical competition between 
thymidine in the Ham’s F-12 medium and the IUdR in the medium overlay, that CHO cells 
preferentially incorporate thymidine from the Ham’s F-12 medium before taking up IUdR via the 
salvage pathway. In the salvage pathway, nucleotide bases are recovered from the medium and 
reconnected to a ribose unit. In a different DNA synthesis pathway (de novo) the nucleotide 
bases are assembled using basic nutrients in the medium. Most animal cells can synthesize 
purine and pyrimidine nucleotides de novo from simpler carbon and nitrogen compounds, rather 
than from already formed purines and pyrimidines (Lodish et al. 1995). However, according to 
Kinsella (1996), IUdR is incorporated into DNA via the enzymes of the salvage pathway.  
The other possibility is the differences in activities of mismatch repair (MMR) enzymes. 
Berry et al. (1999) demonstrated that human colon cancer cells deficient in mismatch repair 
incorporate and retain 2-3 times as much IUdR in their DNA as their normal counterparts. No 
studies have been found reporting MMR deficiency in 9L or other glioma cell lines. 
Table 2.1: Percent thymidine replacement in CHO 
cells versus rat 9L glioma cells. CHO data reported 
by Dugas et al. (2011). Incubation period was 27 
hours for the indicated concentrations of IUdR. 
IUdR concentration 
(μM)
CHO cells 9L glioma cells
1.65 - 11.5 % ± 1.1%
2 5.7% ± 0.1% 15.1% ± 1.2%
5 9.2% ± 1.3% 26.4% ± 0.85%
10 12.0% ± 1.4% 27.7% ± 2.95%
20 16.6% ± 1.9% 35.4% ± 5.62%
Percent thymidine replacement




Results for the mean thymidine replacement (MTR %) versus IUdR concentration (μM) 
in 9L cell cultures after a 27-hour exposure are plotted in Figure 2.1 and listed in Table 2.2. 
Results at 1 μM and 3 μM IUdR of 8.5% ± 0.1% and 17.6% ± 0.1% thymidine replacement 
(%MTR ± σSEM), respectively, were close to the goal of 9% and 18%, respectively. Figure 2.1 
compares a plot of the measured data, mean thymidine replacement versus IUdR concentration, 
with a numerical curve-fit.  
Figure 2.1: Plot of mean thymidine replacement (%) versus IUdR 
concentration (μM). 9L cells were incubated for 27 hours. Measured 
data points (±σSEM) compared with least squares fit to data. 
IUdR concentration # of Total # of Mean thymidine replacement (%) Standard
in overlay (μM) experiments data points (mean ± SEM) deviation
1 4 12 8.5% ± 0.1% 0.4%
2 4 12 13.5% ± 0.2% 0.7%
3 4 11 17.6% ± 0.1% 0.5%
5 3 9 21.7% ± 0.3% 0.8%
Table 2.2: IUdR incorporation as a function of the IUdR concentration in the medium 




CHAPTER 3: AIM 2, CELL SURVIVAL MEASUREMENTS 
Aim 2: Survival curves for rat 9L glioma cells with 0%, 9%, and 18% IUdR will be measured 
with 4 MV x-rays and 25-35 keV monochromatic photon beams. 
3.1 Goal 
The goal of this aim was to measure the difference in survival curves (surviving fraction 
versus dose) for 9L glioma cells as a function of modality (i.e., 4 MV bremsstrahlung versus 25 
keV, 30 keV, and 35 keV monochromatic x-rays) and %IUdR levels (0%, 9%, and 18% 
thymidine replacement in the DNA). To ensure reliable results, photon energies and dose must 
be measured and irradiation geometry must be verified. Also, methods to assess differences in 
survival curves and to determine measurement uncertainties in cell survival data must be utilized. 
3.2 Methods of Measurement & Materials 
3.2.1 4 MV X-Ray Irradiations  
3.2.1.1 Properties of 4 MV Beam 
 4 MV bremsstrahlung x-rays were generated using a Clinac 21EX radiotherapy linear 
accelerator or “linac” (SN 1412, Varian Medical Systems, Inc., Palo Alto, CA). Properties of the 
beam, such as tissue-phantom ratios (TPR) and output factors, are given in Table 3.1. Because 
this is a clinically commissioned linac, the energy is checked during monthly quality assurance 
assessments by qualified medical physicists, as recommended in the American Association of 
Physicists in Medicine (AAPM) TG-40 (Kutcher et al. 1994). During a monthly QA, the dose 
output is measured at two points on the percent depth dose curve, at depths of 5 cm and 10 cm in 
Solid Water® (GAMMEX rmi, Middleton, WI). If the ratio of the two dose outputs are within 
2% of the commissioned value, the energy is considered calibrated. The accelerator tolerances of 





Table 3.1: 4 MV central-axis dosimetry data for Clinac 21EX radiotherapy linac. (a) Tissue-
phantom ratios, (b) output factors for collimator scatter (Sc), patient scatter (Sp), and the 
combined measured scatter for collimator and patient (Sc*Sp). Data are normalized for 10 x 10 
cm
2
 field size, 10 cm depth at isocenter, and 100 cm source to point distance (courtesy of Mary 







3.2.1.2 Geometry for Cell Irradiations 
 The geometry for 4 MV cell irradiations has been described by Dugas et al. (2011). Flat 
bottomed 25 cm
2
 cell culture flasks (MIDSCI, Valley Park, MO) were placed on top of a slab of 
Solid Water® (to provide sufficient backscatter) 5 cm thick and irradiated at a source-to-surface 
distance (SSD) of 150 cm with respect to the base of the flask with a 45 x 45 cm
2
 field size (30 x 
30 cm
2
 at isocenter), at a depth of 0.5 cm in medium (Figure 3.1). The large field size was 
chosen to accommodate the irradiating of up to four flasks at once, and the extended SSD was 








Figure 3.1: Geometry for 4 MV cell irradiations. (a) Schematic of setup (side view) and (b) 




The dose output at the linac’s calibration point (10 x 10 cm
2
 field size and 10 cm depth at 
isocenter) was 0.758 cGy per monitor unit (MU) for water, and the machine dose rate (dose 
output per unit time) of 250 MU*min
-1
 at isocenter (10 x 10 cm
2




3.2.1.3 Determination of Cell Dose 
Dose delivered to the cells were determined by: 
               (3.1) 
where D is dose delivered, D’ is the dose per MU, and MU is monitor units. fcal is the ratio of the 
dose output in water for calibration conditions measured for the month when cells were 
irradiated to the standard value. D’ was derived (see Appendix A) as: 
 
 
     
    (  )    (  )     (     )  
   ( )
   (   )
     
   (   )
   (    )
  (3.2) 
where Do’ = Standard dose output in water for calibration conditions, 
 rc = Collimator field size (isocenter), 
 Sc(rc)*Sp(rc) = Output factors (scatter collimator factor and scatter phantom factor), 
 r = Effective field size at cell irradiation SPD, 
 d = Cell irradiation depth,  
 dm = Depth of maximum dose for 4 MV in water, 
PSF(FS) = Peak scatter factor (PSF) at a certain field size, 





 where SPD = Source to point of calculation distance (source to surface of cells), 
  SPDo = Calibration distance (source to isocenter distance), 




Table 3.2 shows the values used for each parameter in Equation (3.2), where D’ = 0.486 
cGy*MU
-1
. MU is a measure of beam output of a linac, in which 1 MU corresponds to a set 
amount of charge in a transmission ion chamber, which has been amplified to correspond to a 
particular dose. Linacs are calibrated to give a particular absorbed dose under specific conditions 
(i.e., a machine can be calibrated to deliver 1 Gy per 100 MU for a certain depth, field size and 
SSD), where the dose output is calibrated using TG-51 protocol (Almond et al. 1999). An initial 
amount of MUs were estimated using standard monitor unit calculations (Khan 2010) for the 
prescribed doses of 0 cGy, 200 cGy, 400 cGy, 600 cGy, 800 cGy, 1000 cGy, and 1200 cGy. The 
actual dose delivered to the cells was then calculated using Equation (3.2). 
 Each time a 4 MV cell irradiation was done, fcal (i.e., the ratio of the measured dose 
output to standard dose output for a given monthly output QA) of the machine was recorded 
from the official data log book kept at the clinic, which is verified and updated on a monthly 
basis (see Section 3.2.1.1). The purpose of the monthly measurement was to verify that the 
Table 3.2: Parameter values for Equation (3.2). 
Parameters in Equation (3.2) Values
D o ' (d o , FS = 10 x 10 cm
2, SSDo) 0.758 cGy*MU
-1 (dose to water)
r c 30 x 30 cm
2
S c (r c )*S p (r c ) 1.195 (from Table 3.1(b))
d m 1.2 cm
d 0.62 cm [(0.5 + 0.12)cm]
r 44.96 x 44.96 cm2 [45 cm*(149.88/150)]
r dm 29.6 x 29.6 cm
2 [30 cm*(98.8/100)]
TPR (r c ,d m ) 1.248 (interpolated from Table 3.1(a))
TPR (r, d ) 1.152 (interpolated from Table 3.1(a))
TPR (r, d m ) 1.205 (interpolated from Table 3.1(a))
PSF (r )*[PSF (r d m )]
-1 1.010 (interpolated from Aird et al. 1996)
SPD 149.88 cm [(150-0.12)cm]







calibrated dose output was within the clinic’s tolerance of ± 2% of the commissioned value. fcal, 
obtained from the clinic’s logbook, was included in Equation (3.1) to account for monthly output 
fluctuations, which are within the ± 2% tolerance of the standard dose output in water for 
calibration conditions (see Table 3.3 for fcal values for all 4 MV cell irradiations).  
3.2.1.4 Film Verification of Cell Dose 
Radiochromic film was chosen for this project because of its inherent ease in irradiation 
and analysis. Gafchromic® EBT film (ISP, Wayne, NJ) was obtained from lot #48022-05. To 
verify the dose delivered to cells, 3 x 6 cm
2
 pieces of EBT film were placed at the inner bottom 
of the 25 cm
2
 flasks (location of growth surface area for cells) with a 0.5 cm thick layer of Super 
Flab® over the film to simulate the medium that overlay the cells. Then, the flask with film was 
placed in the field along with three cell-bearing flasks.  
Table 3.3: Values of fcal for 4 MV cell irradiations. 
Logbook (i.e., Monthly f cal Irradiation Data Set % IUdR
Measurement) Date Date
06/20/10 1.001 07/07/10 (001) 0
07/16/10 0.995 07/22/10 (003) 0
07/16/10 0.995 08/25/10 (005) 0
10/27/10 1.007 11/04/10 (010) 0
10/27/10 1.007 11/11/10 (011) 0
01/19/11 1.001 02/09/11 (015) 9
01/19/11 1.001 02/16/11 (016) 0
03/16/11 0.994 04/14/11 (022) 0, 9, 18
04/25/11 1.003 05/11/11 (024) 0, 18
05/20/11 1.011 06/15/11 (027A) 0
05/20/11 1.011 06/16/11 (027B) 0, 18
06/20/11 1.011 06/30/11 (030) 0, 18
06/20/11 1.011 07/07/11 (031) 0, 18
06/20/11 1.011 07/14/11 (032) 0, 9
09/20/11 1.008 09/23/11 (043QA) 0
01/23/12 1.008 01/23/12 (061QA) 0
01/23/12 1.008 02/09/12 (065QA) 18




 Following film exposures, film doses were determined using the mean pixel value of a 
region of interest (~1.0 x 1.0 cm
2
) located at the center of the film (film readout and analysis 
protocol was discussed in Brown et al. (2012a) and summarized in Appendix C). The mean pixel 
value, which was proportional to the mean dose delivered to the cell flask, was then converted to 
net optical density (NOD). The NOD was converted to dose using the calibration curve described 
in Brown et al. (2012a) (see Appendix C). This mean dose was then compared to the calculated 
dose. This verification process was performed for two separate days of the 18 days in which 4 
MV cell irradiations were performed. 
3.2.2 Monochromatic keV X-Ray Irradiations 
3.2.2.1 Production of Monochromatic X-Rays (25-35 KeV) 
 Monochromatic x-rays were produced by a synchrotron (LSU Center for Advanced 
Microstructures and Devices (CAMD)). CAMD uses an electron storage ring to produce broad 
spectrum electromagnetic radiation. A linac injects 200 MeV electrons into the synchrotron ring, 
which are then accelerated to 1.3 GeV. The target value for ring current after injection is 200 
mA. Synchrotron radiation is emitted when charged particles are accelerated at relativistic 
speeds. The ring’s bending magnets produce light from UV wavelengths to x-rays of about 1 
keV energy (http://www.camd.lsu.edu/). 
 Producing higher energy x-rays requires stronger acceleration of the electron beam. This 
is achieved with an “insertion device” that laterally accelerates the electrons, oscillating them 
through sharp bends in the plane of the ring. These insertion devices are often called “wigglers” 
because of the motion of the electron beam. Insertion devices are located on straight sections of 
the storage ring, between the bending magnets. The current insertion device, a wavelength shifter 




the central pole and 1.55 T at the side poles (see Figure 3.2(b)). This insertion device produces x-
rays up to a few tens of keV. The broadband synchrotron radiation travels in the direction of the 
axis of the WLS (tangential to the ring) and feeds into the experimental beamlines (Figure 
3.2(a)). One of four beamlines fed by the WLS is the tomography beamline (from herein referred 
to as the radiobiological beamline) (see Figure 3.2(c)).  
 A monochromator is used in the beamline to select a particular narrow x-ray energy beam 
(see Figure 3.2(d)). X-rays refract from the crystal structure of the monochromator, transmitting 
only those x-rays with a wavelength satisfying Bragg’s Law (n*λ=2*d*sinθ). The crystal 
spacing (d) and the Bragg scattering angle (θ), (how much the monochromator crystal must be 
tilted relative to the photon beam) determines the selected a specific energy. The crystal spacing 
also determines the bandwidth (degree of monochromaticity) of the selected energy. The current 
monochromator (Oxford, Danfysik, UK) in the radiobiological beamline is a double-crystal, 
multi-layer (W-B4C) monochromator, used in a grazing incidence geometry. The 
monochromator can transmit 6-35 keV x-rays with a bandwidth of 1-3%. The beam must hit at a 
very shallow grazing angle to produce the higher energies so that small changes in the crystal tilt 
(i.e., incidence angle) produce big changes to the energy. The second crystal redirects the 
monochromatic beam to a path parallel to the original white light. Monochromatic photons enter 
the experimental area (i.e., hutch) through a Kapton® window and pass through tungsten 
collimators to shape the beam.  
 In the present study, monochromatic x-ray beams of 25 keV, 30 keV and 35 keV were 
used. The beam energy was set through calibrations of the monochromator, which were done  
using a K-edge absorption technique where the beam intensity was measured after passing 




discontinuities in absorption as the monochromator passed through the K-edge energy identifies 
the monochromator setting for that energy. By sweeping across a range of beam energies for a 
series of materials with different well-known K-edge energies (i.e., 25.5 keV for Ag, 29.2 keV 
for Sn, etc.), the monochromator was calibrated (Oves 2008). 
 The WLS and monochromator limited the range of energy this project could study. As 
can be seen in Figure 3.3, the dose rate decreased rapidly as the energy increased. At about 40 
keV, the dose rate dropped down to 0.1 Gy*min
-1
 at 100 mA. At energies > 40 keV, the dose rate 
would be too low for cell irradiations to be feasible. 
Figure 3.2: Production of monochromatic x-rays for radiobiological beamline at CAMD. (a) 
Schematic overhead view of CAMD synchrotron and beamlines. (b) Illustration of photons 
traversing a 3-pole WLS. (c) Expanded view showing the radiobiological beamline utilized in 
this project. (d) Simple schematic of incident white light selecting a small bandwidth of the light 





3.2.2.2 Time Variation of Beam Current  
 As part of normal operations at CAMD, the number of electrons cycling the storage ring 
decreases exponentially with time after initial injection. Therefore, the photon intensity produced 
by these electrons passing through the wiggler simultaneously decreases. As a result of the 
decreasing fluence from the decaying storage ring current of the beam, the dose rate was 
dependent on the beam current at the time of measurement. To compensate, beam current was 
recorded at each measurement. Figure 3.4(a) shows a typical plot of ring current decaying as a 
function of time over one day at CAMD. Usually, electron injection occurred around 8:15 AM; a 
beam dump and re-injection occurred around 2:30 PM. At the beginning of a completed 
injection, the current was ≤ 200 mA. Re-injection was done to keep the beam current from 
getting too low (below ~80 mA). Figure 3.4(b) shows an example of a day with three electron 
injections (one morning injection followed by two afternoon re-injections).  
Figure 3.3: Estimated dose rate at 100 mA based on measured 
dose rate and calculated beam fluence as a function of energy 




3.2.2.3 Energy Verification 
  Prior to dose measurements and cell irradiations, the energy of the beam was verified 
using a powder diffraction measurement (described in Oves (2008) and Dugas et al. (2008)). The 
beam, which was horizontally collimated using tungsten plates to approximately 0.2 × 0.1 cm
2
, 
was incident upon a Si640c powder sample (0.8 cm in diameter) contained within a 45
◦
 cone 
milled into a 3 mm thick polymethylmethacrylate (PMMA) holder. The sample was aligned at 
beam height, perpendicular to the incident beam. Photons passing through the Si640c sample 
Figure 3.4: Beam current decay at CAMD. (a) Typical day with a 
morning electron injection followed by one in the afternoon. (b) A 





were diffracted according to Bragg’s Law, producing concentric Debye-Scherrer rings (see 
Figure 3.5). A flat panel XRD 0820 CN3 amorphous silicon detector (Perkin-Elmer, Waltham, 
MA) was used to capture the Debye-Scherrer rings. Each measurement required an exposure 
time of 2 s and allowed determination of the energy to within ± 0.1 keV (Brown et al. 2012b).  
 
Figure 3.5: Schematic for energy determination. (a) Schematic showing the 
incident monochromatic, “point” beam being diffracted by Si640c crystal powder 
producing Debye-Scherrer diffraction cones (courtesy of Dr. Thomas A.D. 
Brown). (b) Typical image of Debye-Scherrer diffraction rings intersecting and 
being recorded by the flat panel, digital x-ray detector. X-ray wavelength, 
determined by the cone angle [n*λ = 2*d*sin (0.5*arctan(R/L)] allow 




3.2.2.4 Production of Broad Beam Monochromatic X-Rays 
 Due to physical restrictions imposed by synchrotron emission, the monochromator, and 
the beamline slits, the monochromatic beam in the hutch measured approximately 3.0 cm 
horizontally (plane of synchrotron ring) by 0.1 cm
 
vertically. This “strip” beam was filtered 
using 640 μm aluminum to remove low-energy x-ray contamination (see Figure 3.6). An 
Figure 3.6: Synchrotron “strip” x-ray beam. (a) 
Monochromatic beam filtered by aluminum foil (640 
μm thick) and collimated with tungsten beamline 
slits to 3.0 x 0.1 cm
2 
dimensions. (b) Resulting 





effective broad beam approximately 3.0 x 2.5 cm
2
 was achieved by vertically oscillating the 
irradiation target through a triangular waveform through the path of the narrow beam to 
uniformly distribute dose to the cells (see Figure 3.7). A screw-drive motion stage (Velmex, Inc., 
Bloomfield, NY) controlled by an in-house LabVIEW  (National Instruments Corporation, 
Austin, TX) interface was used to achieve the target oscillation (Dugas et al. 2008, Oves et al. 
Figure 3.7: Broad beam production. (a) A screw-drive motion stage, 
with a cell culture test tube attached, oscillates through the 
monochromatic x-ray beam producing a broad beam in the reference 
frame of the cell culture test tube. (b) An effective broad beam 
approximately 3.0 x 2.5 cm
2
 was achieved by vertically oscillating the 
stage through the path of the “strip” beam at 0.125 cm*s
-1
 using a 




2008). Previous measurements showed that the effective broad beam can be considered a parallel 
beam (Dugas et al. 2008).  
3.2.2.5 Geometry for Cell Irradiations 
 Cell culture test tubes (3 cm wide x 10 cm long) were filled with ~35 mL of medium and 
attached to the motion stage using a PMMA holder. The holder was oriented (17
o 
from 
horizontal) so that the cell growing surface, located on the inner flat side of the tube, was at an 
angle of 26
o
 to the incident beam for uniform dose coverage (see Figure 3.8). Upon activating the 
scanning operation, the motion stage moved rapidly downward until the beam was incident on 
the bottom edge of the tube. At this point, the stage slowly moved (0.125 cm*s
-1
) downward 
through the 2.5 cm amplitude of the beam and then upward 2.5 cm in multiple stage oscillations 
(one oscillation = ± 2.5 cm), sweeping the tube and uniformly irradiating the growing surface 
Figure 3.8: Geometry of monochromatic x-ray cell irradiations. Schematic showing 
relationship between oscillating stage, cell culture test tube mount, cell culture test tube, 




completely (described in Dugas et al. 2011). The speed of the movement was set sufficiently low 
to minimize the change in exposure time due to the change in acceleration at the stage’s lowest 
and highest position. The transit time of a complete stage oscillation (i.e., one stage cycle) was 
40 s. The number of cycles was rounded to the nearest whole number that would approximately 
achieve the prescribed dose. Upon completion, the stage rapidly moved upward and out of the 
beam to its original position. 
3.2.2.6 Determination of Cell Dose 
 Two independent methods were utilized to determine the monochromatic x-ray beam 
dose delivered to the cells, ion chamber and radiochromic film dosimetry. The former was used 
to determine the cell irradiation times at the beginning of an experiment. Because this was often 
shortly after beam injection, it is believed that the dose rate (Gy*min
-1
 per 100 mA) settled to a 
different value. Hence, radiochromic film dosimetry, typically done just before irradiating 
multiple cell culture test tubes, was used as the primary measured cell dose.  
3.2.2.6.1 Ion Chamber Dosimetry 
The first step to determine the doses delivered to the cell cultures was to take ion 
chamber measurements at a depth of 0.58 cm in a PMMA phantom to estimate the dose rate at 
100 mA (see Figure 3.9). The estimated dose rate was used to determine the required number of 
cycles for each cell irradiation. Three measurements were taken, each lasting 320 s, 
corresponding to eight cycles. Using the average ring current for each irradiation, the measured 
ionization was normalized to a ring current of 100 mA, converted to a dose using AAPM TG-61 
(Ma et al. 2001) protocol as described below, and then divided by 320 s to get a normalized dose 
rate. The average dose rates at 100 mA were 0.2 Gy*min
-1
 at 35 keV, 0.8 Gy*min
-1
 at 30 keV, 
and 1.5 Gy*min
-1




 The TG-61 protocol for determining dose to water (Dw) for medium-energy x-rays (100-
300 kV) at a depth of 2 cm, was applied to convert the ion chamber readings (normalized to 100 
mA) into dose: 
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(3.3) 
where: 
 Mnorm = Electrometer reading (C), 
 Pelec = Electrometer calibration factor, 
Figure 3.9: Ion chamber measurements. (a) Schematic showing dose calibration beam geometry 
(courtesy of Dr. Thomas A.D. Brown). (b) Phantom slab that contains insertion for ion chamber. 




PTP = Ambient temperature and pressure correction factor (corrected to T = 22
o
C, P = 
101.33 kPa), 
 Pion = Ion recombination correction factor, 
 Ppol = Polarity effect correction factor, 
Nk = Air-kerma calibration factor (Gy*C
-1
) of the 0.23 cm
3
, air-equivalent cylindrical ion 
chamber (Scanditronix Wellhofer GmbH model FC23-C, Schwarzenbruck, 
Germany),  
PQ, cham = Overall correction factor to account for the effects due to the change in beam 
quality between calibration and measurement and to the perturbation of the 
photon fluence at the point of measurement by the chamber, 
           (
   
 
)
    
     
= Ratio of the water-to-air mass-energy absorption coefficients.  
Because the studied energies (25-35 keV) were at or slightly below the range specified for the 
TG-61 protocol (the effective energy of 100 kV is approximately 33 keV), its use was validated 
by Brown et al. (2012b) performing fluence measurements (see Appendix C).  
 The factors in Equation (3.3) were obtained in the same manner as described in Brown et 
al. (2012b), and are listed for all energies studied in Table 3.4. Pelec was determined by an 
Accredited Dosimetry Calibration Laboratory (ADCL). The temperature and pressure were 
recorded before and after each ion chamber measurement using a NIST-traceable digital 
thermometer/barometer placed on the oscillating stage and averaged for each measurement. PTP 
was determined by: 
 
     
          
     
 
      








 T = Temperature (
◦
C), 
 P = Absolute Pressure (kPa). 
The ion chamber measurements used to calculate Pion and Ppol were conducted at a 
PMMA depth of 0.58 cm. The application of the TG-61 protocol to determine the ion chamber 
depth-dose curve was validated by intercomparison with MCNP5 Monte Carlo calculations of 
dose per fluence and measured fluence at beam energies of 25 and 35 keV as done by Oves et al. 
(2008) and briefly discussed in Appendix C. 
 Ion chamber readings (Mraw) for Pion and Ppol lasted 160 s (i.e., four cycles) and were 
normalized to a ring current of 100 mA. Pion was determined for the case of a continuous beam 
using high and low electrometer bias voltages of -300 V (VH)  and -150 V (VL) , respectively (see 
Equation (3.5) below). Ppol was determined for the case of electrometer bias voltages of +300 V 
(M
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   (3.5) 
Table 3.4: TG-61 ion chamber calibration and correction factors for dose calculations 
using Equation (3.3) at 25, 30, and 35 keV (Brown et. al 2012b). Measurements of PTP, 
Pion, and Ppol were repeated for each set of depth-dose measurements, and the range of 
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(3.6) 
 Values for PQ,cham were difficult to determine because the energies and field size used for 
these measurements lay outside the range of data available for this correction factor in TG-61. 
Estimates of PQ,cham were obtained by using PQ,cham = 0.995 for the similar NE2611/NE2561 ion 
chambers and for a 0.1 mm Cu half-value layer (HVL) beam (equivalent monochromatic beam = 
33 keV) in TG-61 Table VIII, and then applying a field size correction factor of 1.005 by 
extrapolating data in TG-61 Figure 4 for the broad beam size (7.5 cm
2
) used. Nk was determined 
using a linear fit to ADCL-calibrated values measured for a 120 kVp beam (HVL = 6.96 mm Al) 









, respectively. The HVL values were used to interpolate or extrapolate Nk values at 35 keV 
(HVL = 3.33 mm Al), 30 keV (HVL = 2.28 mm Al), and 25 keV (HVL = 1.12 mm Al). Mass-
energy absorption coefficients for water and air were interpolated for each energy using NIST 
tables (Hubbell & Seltzer 2004) and used to calculate values for (
   
 
)
    
     
. 
 Ion chamber dose rates were considered an estimate for two reasons: (1) differences in 
depth of measurement and (2) attenuation due to different materials. During ion chamber 
readings, the ionization was collected at a depth of 0.58 cm through PMMA, whereas cell dose 
was delivered at a depth of 0.31 cm in polystyrene: 
                                         (                  )
      
 
 
        (            )
      
          
(3.7) 
Oves et al. (2008) reported that at depths of less than 1.5 cm in the PMMA phantom, the depth 




measure the dose rate for each electron injection of the beam. Despite the measurement 
difference with respect to the in-phantom depth of 0.58 cm and TG-61’s reference depth of 2 cm, 
the dose rate estimate was acceptable for the purpose of determining the number of stage cycles 
necessary for cell irradiations. 
The ion chamber depth-dose measurements in PMMA were compared with MCNP5 
Monte Carlo calculations of dose per fluence and measured incident fluence to verify the validity 
of using TG-61 ion chamber dosimetry to calibrate dose output (dose per unit time per 100 mA) 
for cell irradiations, as described in Brown et al. (2012b). The methods are briefly described in 
Appendix C. Results showed that TG-61 ion chamber dosimetry agreed with fluence-normalized 
MCNP5 calculations to within 7% at 25 keV and 3% at 35 keV. 
3.2.2.6.2 Radiochromic Film Dosimetry 
Gafchromic® EBT2 film (ISP, Wayne, NJ) obtained from lot # A02181103 (EBT2) was 
used for monochromatic x-ray film dosimetry. After the dose rate per 100 mA was estimated and 
before a set of cell irradiations, two pieces of film were irradiated to later determine more 
accurately the dose to the cells.  A 1.5 x 3.0 cm
2
 piece of film was taped to the cell growing 
surface inside a cell culture test tube which was then filled with water to simulate the effect of 
the medium (Figure 3.10). The tube was then irradiated with the number of stage cycles required 
to acquire ~2 Gy dose. The amount of time taken to deliver this dose and the ring current during 
this time interval were recorded. This measurement was repeated with a second piece of film. It 
was assumed that the average dose delivered to these pieces of film more closely represented the 
actual dose rate during a cell irradiation than did the ion chamber measurement, and hence was 
used to determine the dose delivered to the cells. These film irradiations were repeated for each 




 Next, the pieces of film were scanned and analyzed by a medical physicist at least 24 
hours after the irradiations in the manner described in Brown et al. (2012a) (see Appendix C). 
Briefly, the mean pixel value of an approximately 0.5 x 0.5 cm
2
 region of interest located in the 
center of the film was determined for each piece of film and converted to NOD. Using the 
calibration curve at that particular monochromatic energy, the dose to each piece of film was 
determined and then normalized to 100 mA using the average ring current during each film’s 
irradiation. Each film’s dose at 100 mA was then divided by the amount of time it took to 
irradiate it to compute the dose rate at 100 mA. The two dose rates were averaged and the 
average dose rate (Gy*min
-1
) at 100 mA was used to calculate dose to each cell culture test tube. 
Because the film was placed inside the test tube where the cells would normally be located, no 
correction due to the attenuation of polystyrene was applied to the dose rate calculation. 
 To calculate the total dose to each cell culture test tube, a summation of the dose per five-
minute interval was calculated to account for the beam current decay. Each of these “interval 
doses” was calculated by multiplying the dose rate at 100 mA by the average ring current during 
the five-minute interval, dividing by 100 mA, and multiplying by the time interval (i.e., five 
minutes). 
Figure 3.10: Bird’s-eye-view of radiochromic film attached to 
cell culture test tube. The film was attached to the inside wall 




3.2.2.7 Comparison of Ion Chamber & Radiochromic Film Dosimetry 
For each measurement session, film and ion chamber measurements were taken. Ideally, 
the two methods would agree within a few percent. Upon comparison, however, film and ion 
chamber measurements differed greatly (i.e., by as much as ~ 28% for 35 keV on average). It is 
believed that these discrepancies were due to the timing between the ion chamber and film 
measurements. To investigate this discrepancy, measurements were done to more closely 
compare the two dosimetry methods. Ion chamber measurements were made on four different 
days, approximately one hour after re-injection and followed by film irradiations. On a different 
day, ion chamber measurements were taken during the time interval 3-7 hours post-injection as a 
function of ring current in order to check the stability of the synchrotron beam. 
The estimated cell dose rates calculated using the ion chamber ionization measurements 
in a PMMA phantom were compared to the film dose rate calculated from the pieces of film 
placed inside a test tube and irradiated to ~ 2 Gy (methods described in Section 3.2.2.6).  
3.2.3 Cell Irradiations 
Cells were irradiated by exposing the cell culture test tube to x-rays for the number of 
stage cycles determined from ion chamber measurements for the prescribed dose. The ring 
current was recorded at five-minute intervals during the irradiation. Although the beam current 
decayed exponentially over the course of the day, this was approximated as a linear decay during 
these short five-minute intervals.  
3.2.3.1 Timeline for Production of a Cell Irradiation Data Set 
Multiple steps were required to produce a cell irradiation data set and construct a survival 
curve. Table 3.5 outlines the steps and timing of each action performed. Cell preparations pre-




steps were growing cells (Day 1), exposing cells to IUdR (Day 2), irradiating cells (Day 3), 
incubating cells (Days 3-12), and fixing/staining/counting cell colonies (Days 12-13). 
The standard protocol outlined in Hall and Giaccia (2006) to produce an in vitro cell 
survival curve was followed (see Figure 3.11). Cells from a stock culture were prepared on Day 
1 into a single-cell suspension by trypsinization, and the cell concentration was counted using a 
hemocytometer (Hausser Scientific, Horsham, PA). Based on hemocytometer counts, 
approximately 2 x 10
4
 cells were plated into each of three cell culture flasks (this number of cells 
were chosen so that, if the cells were to contain IUdR, the cell density was low enough to avoid 
overcrowding but large enough to have good statistics in the number of cells that took up the 
IUdR). These flasks were plated 12-24 hours before the addition of IUdR in order to allow cells 
to recover from the arrest caused by trypsinization.  
On Day 2, if the cells were to contain IUdR, they were fed with 7 mL of medium 
containing either 1 µM or 3 µM of 5’-iodo-2’-deoxyuridine, i.e., IUdR (Sigma-Aldrich, St. 
Louis, MO). After 27 hours of incubation (Day 3), the cells were re-plated following the same 
process used on Day 1. For 4 MV irradiations, cells were cultured in 25 cm
2
 (plating area) flasks 
Table 3.5: Timeline of steps/actions 
performed for each cell irradiation data 
set. 
STEP ACTION TIMELINE
1 Plate Cells Day 1
2 Expose Cells to IUdR Day 2
3 Re-plate Cells Day 3
4 Irradiate Cells Day 3
5 Re-feed Cells Day 3
6 Incubate Cells Day 3
7 Re-feed Cells Day 7
8 Fix & Stain Cell Colonies Day 12




while for 25-35 keV x-rays, cells were cultured in 10 cm
2
 tube flasks. Known numbers of cells 
were plated into cell culture flasks. The number of cells plated per cell culture flask varied with 
dose so that ideally 30-60 cell colonies would survive. This amount of cell colonies should not 
overlap each other nor be too sparse to produce good statistics. Table 3.6 illustrates the cells 
plated and surviving cell colonies for a sample data set. The cells were incubated for 1.5-2 hours 
before transporting to the irradiation site to allow cells to attach to the surface of the cell culture 
flasks. Because irradiations took several hours at CAMD, irradiated cell culture test tubes were 
kept in an incubator on site except while being irradiated. After irradiation, the cells were 
transported back to PBRC where they were re-fed with fresh medium to eliminate radiation-
induced oxygen species that were produced in the medium during irradiations.  
Figure 3.11: Cell culture technique used to measure an in 




During the nine days of incubation (Days 3-12), the cells were allowed to grow until they 
produced macroscopic colonies that can be seen by eye. To replenish nutrients, the cells were re-
fed approximately midway through the incubation period (Day 4). On Day 12, colonies were 
fixed and stained with 2% W/V crystal violet and allowed to air-dry overnight. Figure 3.12 
shows pictures of stained cells and cell colonies. 
 Cell colonies were counted on Day 13 with the aid of a light box, and if needed, a 
magnifier. Cell colonies of ~ 50 cells or more were scored as survivors. The counting of cell 
colonies can be subjective; however, so long as the counter is consistent with what he or she 
Table 3.6: Number of cells plated per 
cell culture flask for data set (065). 
The number of cells plated varied with 
dose to ensure produce good statistics. 
Prescribed Estimated # Surviving







Figure 3.12: Rat 9L glioma cells after fixing and staining with crystal violet. (a) A 4 x 3 mm
2
 
picture of single cells. (b) A 4.75 x 3.75 mm
2
 picture of cell colonies taken using a phase-




considers a surviving colony, the plating efficiency correction minimizes subjectivity. General 
criteria used to judge whether or not a cell colony was a survivor (personal communication with 
Dr. Marie Varnes) were:  
1. Size: The most important factor considered was the size of the cell colony compared to 
others on the cell culture flask. Although most cell colonies that were visible to the naked eye 
were often counted as survivors, small, barely visible cell colonies were not considered 
survivors (see Figure 3.13).  
2. Cell Density of Colony: If a cell colony was too sparse (i.e., a lot of space was visible 
between the stained cells), then the colony will most likely not continue to be clonogenic, 
thus, not be a survivor. Usually the crystal violet stain facilitated the interpretation of how 
dense the colony was (the relatively deeper the purple, the more cells were in the colony). 
3. Well Defined Borders: Healthy colonies had well defined borders, while non-clonogenic cell 
colonies oftentimes had fuzzy borders with what appeared to be “fragments” and “giants” 
around the periphery. Giants are radiation-induced lethally damaged cells; giants are unable 
to divide, hence are not survivors (see Figure 3.14). Figure 3.13 and Figure 3.14 demonstrate 
several examples of cell colonies considered survivors and non-survivors.  
  For each data set, multiple cell culture flasks at a particular %IUdR were irradiated at 
different doses to create a survival curve. Each survival curve was repeated a minimum of three 
times on different days. Cell survival curves were determined at 6-7 dose levels between 0 and 








Figure 3.13: Cell culture test tubes and flasks with stained surviving 
colonies. A red circle around a cell colony denotes the borderline size 
considered a survivor. (a-c) 25-35 keV x-ray exposed cells and (d-e) 4 




3.2.3.2 Determination of Survival Fractions (SF) & Uncertainties 
A single data set (j) at one defined experimental condition (E, %IUdR) had Nj data points 
representing surviving fraction (SFi) at each dose Di. For a single data point “i” at Di, the 
surviving fraction is given by:  
Figure 3.14: Examples of colonies that were 
survivors and non-survivors. (a) Surviving, non-
surviving and borderline size surviving cell colonies, 
magnified by phase-contrast microscope. (b) Close-
up of non-surviving colony. Note the “giants” 
(lethally radiation-damaged cells) around the 
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where: 
    (  ) = Number of cell colonies counted for the i
th
 data point after exposure at  
dose Di, 
    (  ) = Average number of cells plated for exposure at dose Di, 
 PE = Plating efficiency. 
Because the surviving fraction at D = 0 is unity, by definition, the plating efficiency theoretically 
is given by: 
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where  ̅  and  ̅  are the true mean values for the number of colonies counted and number of 
cells plated, respectively, at D = 0, which can only be estimated. The PE was determined as a 
free parameter in the curve-fitting process (see Section 4.2.2). Prior to the fit, Equation (3.9) was 
calculated using an initial estimate of PE given by: 
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 The uncertainty in SFi(Di) was estimated using Poisson statistics for the number of plated 
cells and the number of counted cells, i.e.,: 
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assuming      and  ̅    are uncorrelated. 
3.3 Results & Discussion 
3.3.1 4 MV Film Verification of Dose 
Doses calculated using Equation (3.1) were used as the doses received by the cells 
exposed to 4 MV x-rays. The doses were independently verified using radiochromic film on two 
exposure days. Table 3.7 compares the calculated doses used to determine cell doses, with those 
of two measured film doses. The percent differences (%) between film and calculated doses were 
determined, and the mean percent difference (± standard error) was 5.78 ± 0.58%. 
Table 3.7: Percent differences (%) for MU dose calculations compared to 
measured film doses. 
Date of Irradiation MU Calculated dose (cGy) Film dose (cGy) % diff
(MAY 28, 2010) 426 203.8 187.2 -8.16
851 406.5 382.6 -5.90
1277 610.3 585.7 -4.04
1703 814.1 755.6 -7.19
(JULY 22, 2010) 426 203.0 188.9 -6.93
851 404.9 389.0 -3.92
1277 607.9 589.6 -3.00
1703 810.8 762.6 -5.94






Why the film doses underestimated the calculated doses by 5.8% is not immediately 
apparent. The lack of phantom material lateral to the flasks could have a small but not likely 
significant impact to dose compared to 5.8%. Another possibility is that 0.62 cm depth is in the 
build-up region of central-axis depth dose. Another consideration is the erroneous assumption 
that non-uniform off-axis ratios near dmax were negligible. A fourth possibility is some unknown 
error in the film calibration. 
A difference of this magnitude warrants further investigation. First, these measurements 
should be repeated, and if the difference remains, a third dosimeter, such as TLD-100 powder 
should be used as a second check. Second, a phantom housing the film with materials 
surrounding the flasks should be used so as to repeat the film measurement with a geometry 
more closely simulating that of the calculated. 
Furthermore, future 4 MV cell exposures should be made at a depth just beyond dmax = 
1.2 cm (e.g., 1.5 cm), so as to be out of the dose build-up region. This could be accomplished 
with an additional build-up plate or by adding more medium to the flasks. Finally, off-axis ratios 
(OAR) should be considered in the calculation of dose. 
3.3.2 Monochromatic X-Ray Energy Measurements 
Table 3.8 lists the monochromatic x-ray energy measurements made for each cell 
irradiation session at CAMD. For each day listed (data not shown) the average ± standard error 
of the mean was calculated from three measurements. The collective average (± standard 
deviation) for each energy were 36.03 ± 0.24 keV for a nominal setting of 35 keV, 30.53 ± 0.11 
keV for 30 keV, and 25.42 ± 0.20 keV for 25 keV.  
 In the method of energy tuning at the radiobiological beamline, the beam passes through 




a particular energy. These grazing incidence angles are small and get smaller at higher energies; 
as the energy gets higher, the acceptance angle decreases. Photon energies of 35 keV is at the 
high end of the energy range of the radiobiological beamline (tunable energy range is 6-40 keV), 




 for 36 keV (private 
communication with Dr. Kyungmin Ham). Therefore, the 0.24 keV sigma corresponds to a 
Table 3.8: Energy measurements with the average (± standard deviation) energy of 
these measurements. 
E = 35 keV E = 25 keV
Date Energy (keV) Standard Error Date Energy (keV) Standard Error
3-Dec-10 35.92 0.04 25-Aug-11 25.48 0.05
17-Dec-10 35.88 0.09 31-Aug-11 25.61 0.04
2-Mar-11 36.44 0.11 9-Sep-11 25.28 0.04
7-Apr-11 36.23 0.07 14-Sep-11 25.63 0.06
28-Apr-11 36.17 0.07 14-Sep-11 25.58 0.09
20-May-11 35.93 0.12 22-Sep-11 25.48 0.03
8-Jun-11 36.15 0.12 23-Sep-11 25.39 0.05
8-Jun-11 36.06 0.07 7-Oct-11 25.33 0.02
24-Jun-11 36.12 0.09 13-Oct-11 25.46 0.03
22-Jul-11 35.98 0.07 21-Oct-11 24.83 0.04
12-Aug-11 36.04 0.12 17-Nov-11 25.64 0.03
29-Sep-11 36.22 0.07 18-Nov-11 25.36 0.06
12-Oct-11 36.00 0.09 13-Dec-11 25.41 0.07
26-Oct-11 35.33 0.04 2-Feb-12 25.62 0.05
1-Mar-12 35.92 0.10 15-Feb-12 25.22 0.03
23-Feb-12 25.43 0.07
Average 36.03
Standard 0.24 Average 25.42
Deviation Standard 0.20
Deviation
E = 30 keV














sigma in the grazing angle of 0.004
o
 (22.2π μradians). This means that accurate energy selection 
at high energies is severely limited by the mechanical accuracy of the grazing angle adjustment. 
Although irradiations were not always at exactly the same energy, and had an average of 36 keV 
and were > EK of iodine, this difference from the target value of 35 keV should have little impact 
on the results. 
3.3.3 Dose Rate Intercomparison between Ion Chamber & Film Measurements 
The dose rates per 100 mA calculated from ion chamber measurements were compared 
with those measured from the film irradiated immediately before cell irradiations. The ion 
chamber dose rates were normalized to the equivalent film depth in PMMA using fractional 
depth dose values derived from MCNP5 simulations (since the ion chamber was irradiated in 
PMMA and the film was irradiated in the polystyrene test tube, the irradiation depth for film 
measurements was converted to equivalent depth in PMMA). Table 3.9 compares the mean film  
dose rate (determined from averaging the measured dose rates of two pieces of film irradiated 
consecutively inside a cell culture test tube), and mean ion chamber dose rate (calculated by 
averaging the three ionization measurements made consecutively inside a PMMA phantom) for 
each monochromatic x-ray irradiation.  
 The mean percent difference ± standard deviation between ion chamber dose rate and 
film dose rate per 100 mA were 27.5 ± 14.1% for 35 keV, 24.7 ± 3.9% for 30 keV, and 13.3 ± 
6.0% for 25 keV, with the ion chamber measurements always overestimating the dose rate 
compared to film. These discrepancies are mostly likely a function of the timing between ion 
chamber measurements and film irradiations. The ion chamber measurements were usually made 




Table 3.9: Dose rate per 100 mA (± standard error of the mean) intercomparison between ion 
chamber and film measurements. Measurements made for beam energies of (a) 35 keV, (b) 30 
keV, and (c) 25 keV. Note that earlier in this project (9-10-2010 through 4-8-2011) only one set 
of film irradiations were done per experiment, for any number of re-injection cycles that 
occurred. In these cases, the film dose rate was scaled by the ratio of the ion chamber dose rates 
to calculate the dose to the cells. 
 (a)   Energy = 35 keV
Date Mean film dose rate SEM Mean IC dose rate SEM Mean IC dose rate %
of irradiation (Gy*min-1*100mA-1) at IC depth at film depth difference
(Gy*min-1*100mA-1) (Gy*min-1*100mA-1)
9/10/2010 0.246 1.52E-04 0.277 0.001 0.287 -16.7
10/7/2010 0.188 0.004 0.234 0.006 0.242 -28.8
3/2/2011 0.089 0.001 0.103 0.002 0.107 -19.8
3/4/2011 0.060 3.25E-04 0.071 0.001 0.074 -23.6
4/6/2011 0.123 0.001 0.160 0.002 0.165 -34.3
4/7/2011 0.104 0.002 0.166 0.004 0.171 -65.0
4/8/2011 0.086 0.001 0.089 0.002 0.092 -7.1
4/28/2011 0.113 0.001 0.160 0.002 0.166 -46.7
5/19/2011 0.094 0.002 0.138 0.001 0.143 -51.9
0.106 0.002 0.137 0.002 0.141 -33.7
7/20/2011 0.118 0.003 0.160 0.002 0.165 -40.5
0.126 0.001 0.156 0.002 0.162 -28.9
7/21/2011 0.127 0.001 0.169 0.004 0.175 -37.3
0.139 0.004 0.169 0.003 0.175 -26.1
7/22/2011 0.141 0.001 0.169 0.003 0.175 -23.7
0.143 - 0.178 0.004 0.184 -28.6
8/11/2011 0.149 0.004 0.185 0.003 0.192 -29.1
0.143 0.002 0.174 0.004 0.181 -26.3
8/12/2011 0.134 3.46E-04 0.175 0.004 0.181 -35.7
0.134 0.003 0.164 0.002 0.170 -26.8
8/17/2011 0.113 0.003 0.154 0.003 0.160 -41.3
9/28/2011 0.318 0.005 0.328 0.001 0.340 -6.8
9/29/2011 0.292 0.002 0.315 0.001 0.326 -11.6
0.324 0.003 0.339 3.26E-04 0.351 -8.5
10/12/2011 0.278 0.001 0.310 0.001 0.321 -15.6
10/20/2011 0.308 0.001 0.333 0.001 0.345 -12.2
10/27/2011 0.297 1.18E-05 0.330 0.001 0.342 -14.9





Table 3.9 (continued) 
(b)   Energy = 30 keV
Date Mean film dose rate SEM Mean IC dose rate SEM Mean IC dose rate %
of irradiation (Gy*min-1*100mA-1) at IC depth at film depth difference
(Gy*min-1*100mA-1) (Gy*min-1*100mA-1)
11/18/2011 0.768 0.009 0.861 4.87E-04 0.901 -17.3
12/2/2011 0.661 0.003 0.823 0.003 0.860 -30.2
12/7/2011 0.659 0.002 0.783 0.001 0.819 -24.3
12/9/2011 0.682 0.002 0.783 0.001 0.819 -20.0
2/3/2012 0.689 0.026 0.861 0.009 0.900 -30.6
0.709 0.005 0.840 0.010 0.879 -23.9
2/16/2012 0.698 0.005 0.822 0.004 0.860 -23.2
2/23/2012 0.706 0.005 0.848 4.84E-04 0.887 -25.6
2/24/2012 0.704 0.018 0.855 0.016 0.894 -26.9
0.705 0.024 0.843 0.008 0.882 -25.1
2/29/2012 0.688 0.001 0.821 0.012 0.859 -24.8
0.710 0.012 0.818 0.011 0.855 -20.4
3/1/2012 0.679 0.005 0.836 0.004 0.875 -28.7
Mean % difference -24.7
Standard Deviation 3.9
(c)   Energy = 25 keV
Date Mean film dose rate SEM Mean IC dose rate SEM Mean IC dose rate %
of irradiation (Gy*min-1*100mA-1) (Gy*min-1*100mA-1) at film depth difference
(Gy*min-1*100mA-1)
8/26/2011 1.455 3.54E-04 1.492 0.001 1.606 -10.4
8/31/2011 1.416 0.009 1.467 0.005 1.578 -11.5
9/1/2011 1.429 0.016 1.516 0.003 1.631 -14.2
9/8/2011 1.405 0.011 1.456 0.004 1.566 -11.5
9/9/2011 1.418 0.012 1.426 0.005 1.534 -8.2
9/14/2011 1.413 0.016 1.428 0.004 1.537 -8.8
1.467 0.002 1.503 0.001 1.617 -10.2
9/15/2011 1.421 0.019 1.437 0.004 1.546 -8.8
11/16/2011 1.748 0.020 1.790 0.002 1.926 -10.2
12/13/2011 1.418 0.005 1.677 0.021 1.805 -27.2
2/15/2012 1.244 0.061 1.433 0.020 1.542 -24.0
1.334 0.065 1.449 0.024 1.560 -16.9
10/21/2011 1.218 0.004 1.256 0.002 1.352 -11.0





was initially less stable, whereas the film irradiations were made at least 1 hour after re-injection, 
right before cell irradiations.   
 Within the first hour of re-injection there were variations (decreases) in the beam output 
(dose per unit time per 100 mA) that was independent of the ring current (mA) right after re-
injection (Brown et al. 2012b). It is believed that these variations are due to thermal changes in 
the radiobiological beamline components (i.e., monochromator). Once the beamline components 
reached thermal equilibrium, the dose rate per mA stabilized. Figure 3.15 shows the decrease in 
dose rate per 100 mA for the 35 keV beam as a function of time. The decrease of 20.7 ± 3.2% 
compares well with the mean of the ion chamber doses overestimating those of the film by 
27.5%. 
Figure 3.16 demonstrates the stability of the synchrotron beam from 3 to 7 hours after 
injection by plotting dose (normalized to 100 mA), as a function of ring current during a period 
of four hours for a 35 keV beam. Ion chamber measurements started three hours after beam re- 
injection and lasted four hours during the period of a single beam injection. The mean dose at 
100 mA (± standard deviation) was 4.83 ± 0.14 Gy and the mean dose rate per 100 mA was 
0.181 ± 0.0051 Gy*min
-1
. These data indicate the dose rate is stable after three hours. 
The major reasons why ion chamber measurements were not done one hour after re-
injection were to not waste beam time and to minimize the total amount of time the cell test tubes 
were away from the tissue culture facility PBRC. At 35 keV, a tube that was prescribed 10 Gy 
would take approximately 50 minutes to irradiate when the dose rate was 0.2 Gy*min
-1
 at 100 
mA. At this rate, irradiating enough cell culture test tubes to create a survival curve (multiple cell 





Figure 3.16: Dose (cGy) at 100 mA versus ring current (mA) for 35 keV during a time period 
of 3-7 hours after re-injection. Time period corresponded to 170−92 mA. Measurements   
using an ion chamber were made on 8/12/2010. The mean dose per 100 mA was 48.3 ± 1.4 
cGy and the dose rate per 100 mA was 0.181 ± 0.0051 Gy*min
-1
. 
Figure 3.15: Fluctuation of dose (cGy) per 100 mA as a function of time after re-injection 




 Although it would be possible to wait until the beam stabilizes to make ion chamber 
measurements, because the purpose of the ion chamber dose rate was solely to estimate the 
number of stage cycles the cell culture test tubes were required to undergo to receive the 
prescribed dose, it was not imperative to accurately determine the dose rate per 100 mA using 
the ion chamber (the film dose rate was used to determine the dose to the cells, not the ion 
chamber dose rate, as discussed in Section 3.2.2.6). 
Thus, the comparison of film with ion chamber dosimetry was best tested for those cases 
in which the ion chamber dose was measured at least 1 hour after injection. Ion chamber 
measurements were made on four different days, approximately one hour post re-injection and 
followed by film irradiations. The mean of three ion chamber measurements were compared to 
the mean of two film dose rate measurements, as shown in Table 3.10. The mean percent 
differences ± standard deviation between the two methods were 13.5 ± 1.9% for 35 keV and 10.6 
± 0.6% for 25 keV (30 keV not measured). Why ion chamber measurements remained 
approximately 12% greater than film is not fully understood. 
3.3.4 Summary of All Cell Irradiation Data 
Table 3.11 shows the list of cell irradiation sessions required for this project. A total of 75 
experimental sessions (75 days) were performed over the span of approximately two years, 
yielding 1,123 data points, of which 906 were usable. A data point was unused for any of the 
following reasons: (1) there was mold contamination in the cell culture tube; (2) the experimental 
session had a plating efficiency that was too low (< 20%); (3) zero dose flasks were unavailable 
for that experiment as a result of plating error or contamination, making it impossible to calculate 
a plating efficiency; (4) the irradiation source was down, preventing cell irradiations; or (5) the 




 Table 3.12 summarizes the usable data by combinations of energy and %IUdR, including 
quality assurance (QA) data (QA data were measured survival curves for the purpose of 
assessing whether 9L cell dose-response continued to be reproducible). Approximately 40% of 
the data were collected for 4 MV, which served as a baseline for this project. The remaining data 
points were distributed amongst the monochromatic energies, with 23% at 35 keV, 18% at 30 
keV, and 19% at 25 keV. Several issues inhibited the collection of data evenly amongst the 
various %IUdR levels per energy. Irradiations at 4 MV were the easiest to collect because of 
several factors: (1) up to four flasks could be irradiated at a time; (2) minimal setup was required 
(3) no prior measurements were required before irradiations, once the EBT film calibration curve 
was established; and (4) the dose rate was constantly high (1.2 Gy*min
-1
). In contrast, 35 keV 
was the most difficult energy for data collection. All monochromatic energies were limited to 
Table 3.10: Dose rate per 100 mA intercomparison between ion chamber and film 
measurements approximately one hour after re-injection. Measurements were done 
consecutively for 35 keV and 25 keV (no measurements were done at 30 keV). 
Film depth in polystyrene tube (cm) 0.305
Film depth in polystyrene tube (g*cm-2) 0.324
Equivalent film depth in PMMA (cm) 0.274
IC depth in PMMA (cm) 0.580
Date 10/20/2012 10/27/2012 10/21/2012 11/16/2012
Energy (keV) 35 35 25 25
MCNP5 FDD at IC depth 1.318 1.318 1.620 1.620
MCNP5 FDD at equivalent film depth 1.364 1.364 1.743 1.743
Mean IC dose rate (Gy*min-1*100 mA) 0.333 0.330 1.256 1.790
Mean IC dose rate (corrected to film depth)
(Gy*min-1*100 mA) 0.345 0.342 1.352 1.926
Mean film dose rate (Gy*min-1*100 mA) 0.308 0.297 1.218 1.748
Ratio (IC dose rate/Film dose rate) 1.122 1.149 1.110 1.102
Mean % difference ± standard deviation
35 keV 13.5 ± 1.9




Table 3.11: List of cell irradiation experimental sessions. A total of 75 
experimental sessions (88 data sets) were done with 1,123 data points collected 
(1 flask per data point), of which 906 were usable and 217 unusable.  
Data Set Date Energy IUdR Conc. Doses # of Flasks # of Flasks
(DS) (μM)* ( 0-12 Gy)† (Used data) (Unused data)‡
1 7/7/2010 4 MV 0 0, 1, 2, 4, 6, 8 18
3 7/22/2010 4 MV 0 0, 2, 4, 6, 8, 10, 12 20 2
5 8/25/2010 4 MV 0 0, 2, 4, 6 10
DA002 9/10/2010 35 keV 0 0, 1, 2, 4, 5, 7 7
DA003 10/7/2010 35 keV 0 0, 2, 4, 5, 7, 9, 10 9
DA004 10/8/2010 35 keV 0 0, 2, 4, 6, 7, 9, 10 7
10 11/4/2010 4 MV 0 0, 2, 6, 10 12
11 11/11/2010 4 MV 0 0, 2, 6, 8, 10 16
13 12/16/2010 35 keV 1 0, 1, 3 11
013B 12/17/2010 35 keV 3 0, 1, 2, 4 11
14 1/19/2011 4 MV 0 0, 4, 6, 10 9
1 0, 2, 4, 6, 8, 10 18
15 2/9/2011 4 MV 1 0, 2, 4, 6 14
16 2/16/2011 4 MV 0 0, 4, 8 7
1 0, 1, 2, 4, 6, 8, 10 15
17 3/2/2011 35 keV 0 0, 2, 5, 6 7
1 0, 1, 2 7
19 3/4/2011 35 keV 1 0, 1, 2, 3 9
021A 4/6/2011 35 keV 1 0, 1, 2, 4 12
021B 4/7/2011 35 keV 0 0, 2, 3, 4, 6, 7 11 1
021C 4/8/2012 35 keV 1 0, 1, 2, 3, 4, 5 16
22 4/14/2011 4 MV 0 0, 4, 10 7
1 0, 2, 4, 6, 8, 10 12 1
3 0, 2, 4, 6, 8, 10 13
023A 4/27/2011 35 keV 0 0, 2, 4, 6, 7 11
023B 4/28/2011 35 keV 3 0, 1, 2, 3 9
24 5/11/2011 4 MV 0 0, 4, 10 9
3 0, 2, 4, 6, 8, 10 18
025A 5/18/2011 35 keV 0 0, 2, 4, 5 9
26 5/19/2011 35 keV 1 0, 3, 5, 7 9
025B 5/20/2011 35 keV 0 0, 2, 7, 9 7
027A 6/15/2011 4 MV 0 0, 2, 4, 8, 10, 12 19
027B 6/16/2011 4 MV 0 0, 8, 12 9
3 0, 2, 4, 6, 8, 10, 12 21 1
28 6/22/2011 35 keV 0 0, 2, 4, 5, 9, 10, 11 14




Table 3.11 (continued)  
 
Data Set Date Energy IUdR Conc. Doses # of Flasks # of Flasks
(DS) (μM)* ( 0-12 Gy)† (Used data) (Unused data)‡
30 6/30/2011 4 MV 0 0, 8, 12 9
3 0, 2, 4, 6, 8, 10, 12 21
31 7/7/2011 4 MV 0 0, 12 6
3 0, 2, 4, 6, 8, 10, 12 20 1
32 7/14/2011 4 MV 0 0, 12 6
1 0, 2, 4, 6, 8, 10, 12 21
033A 7/20/2011 35 keV 1 0, 6, 7, 9, 11 9
033B 7/21/2011 35 keV 1 0, 5, 6, 7, 10, 12 9
34 7/22/2011 35 keV 3 0, 2, 4, 7 9
035A 8/11/2011 35 keV 1 0, 9, 10 5
035B 8/12/2011 35 keV 1 0, 9, 11 7
036A 8/17/2011 35 keV 3 0, 2, 4, 6 6
036B 8/18/2011 35 keV 3 0, 2, 4, 6 6
37 8/26/2011 25 keV 3 0, 3, 5, 8, 9, 11, 13, 14 9 4
38 8/31/2011 25 keV 3 0, 2, 4, 6, 8, 9, 10 17 1
39 9/1/2011 25 keV 1 0, 2, 3, 6, 7, 9, 10 17 1
040A 9/8/2011 25 keV 0 0, 2, 4, 5, 6, 8, 10 18
040B 9/9/2011 25 keV 0 0, 2, 4, 6, 8, 10 18
41 9/14/2011 25 keV 1 0, 2, 5, 6, 7, 8, 10 17 1
42 9/15/2011 25 keV 3 0, 2, 4, 6, 8, 10 17 1
043** 9/23/2011 4 MV 0 0, 2, 4, 6, 8, 10, 12 21
044** 9/28/2011 35 keV 0 0, 3 9
3 0, 3 7
45 9/29/2011 35 keV 0 0, 8 6
3 0, 8 6
47 10/12/2011 35 keV 3 0, 5, 7 9
48 10/20/2011 35 keV 3 0, 3, 4 11
49 10/21/2011 25 keV 0 0, 2, 4, 5, 7, 9, 10 17
50 10/27/2011 35 keV 3 0, 3, 5 12
51 11/16/2011 25 keV 1 0, 2, 4, 6, 8, 9, 10 16 2
52 11/17/2011 25 keV 3 0, 6, 7, 8, 9, 10 13
53 11/18/2012 30 keV 0 0, 2, 4, 6, 8, 10 12
54 12/1/2011 30 keV 0 0, 2, 4, 6, 8, 10 18
55 12/2/2011 30 keV 3 0, 1, 4, 5, 7, 9 14
56 12/7/2011 30 keV 0 0, 2, 4, 5, 6, 9 11 1




irradiation of one flask at a time. Coupling this limitation with a 35 keV dose rate of about 0.2 
Gy*min
-1
 per 100 mA, resulted in, at best, the ability to irradiate 6 cell culture test tubes in one 
day. Because of small effects seen when using 9% IUdR at 25 keV, 9% IUdR data was not 
collected subsequently at 30 keV. 
Table 3.13 shows the mean ± standard error of the mean of the survival of unirradiated 
cells containing the %IUdR levels studied. The mean plating efficiencies ± standard deviation for 
all experiments within each drug level were 46 ± 14%, 47 ± 15%, and 42 ± 16% for 0, 9, and 
18% IUdR. IUdR had little impact on the mean plating efficiency at each IUdR level; however, 
the plating efficiency could vary considerably from one individual data set to another. 
Table 3.11 (continued) 
Data Set Date Energy IUdR Conc. Doses # of Flasks # of Flasks
(DS) (μM)* ( 0-12 Gy)† (Used data) (Unused data)‡
58 12/9/2011 30 keV 3 0, 2, 4, 6, 9, 10 13
59 12/12/2011 30 keV 0 0, 2, 4, 6, 8, 9, 10 19
60 12/13/2011 25 keV 3 0, 4, 5, 7, 8, 9 12 1
061** 1/23/2012 4 MV 0 0, 2, 4, 6, 8, 10 12
62 1/24/2012 4 MV 3 0, 2, 4, 6, 8, 10 13
63 2/2/2012 25 keV 1 0, 2, 4, 5, 7, 8, 9, 10 15
64 2/3/2012 30 keV 0 0, 2, 4, 6, 7, 8, 9, 10 19
065** 2/9/2012 4 MV 3 0, 2, 4, 6, 8, 10 13
66 2/15/2012 25 keV 3 0, 5, 7, 8, 10 14
67 2/16/2012 30 keV 0 0, 2, 4, 6, 7, 9 19
68 2/23/2012 30 keV 0 0, 2, 4, 6, 8, 10 18
69 2/24/2012 30 keV 0 0, 2, 4, 6, 8, 10 18
70 2/29/2012 30 keV 3 0, 2, 4, 6, 8, 10 18
71 3/1/2012 30 keV 3 0, 2, 4, 6, 8, 9, 10 17 1
072** 7/19/2012 4 MV 0 0, 2, 6, 10 9
3 0, 2, 6, 10 9
SUMMARY Total 906 217
* %IUdR vs. IUdR concentration in the medium was 0 μM → 0% IUdR, 1 μM → 9% IUdR,  and 3 μM






Doses were rounded off to the nearest whole number for the purpose of this table.
‡ Data were unused if: contaminated, low PE, no zero dose flasks available, irradiation source down,







Table 3.12: Summary of number of useful data points (cell cultures) 
categorized by energy and %IUdR. QA data points were included. 
Energy 0% 9% 18% # QA Total
IUdR IUdR IUdR data pts
4 MV 148 62 93 64 367
35 keV 47 83 62 16 208
30 keV 97 -- 62 -- 159
25 keV 53 50 69 -- 172
# QA data pts 51 -- 29 80
Total 396 195 315 906
# of Data Points
% IUdR # Data Sets Mean Survival ± SEM σ
0% 34 46% ± 2% 14%
9% 15 47% ± 4% 15%
18% 24 42% ± 3% 16%






CHAPTER 4: AIM 3, DATA ANALYSIS OF CELL SURVIVAL CURVES 
Aim 3: A survival curve will be fit to data for each combination of percent thymidine 
replacement and photon beam energy using a linear quadratic model for surviving fraction, from 
which SER10 values will be determined.  
4.1 Goal 
 The goal for this aim was to analyze surviving fraction versus dose data using a common 
radiobiological model. Such analysis assesses the behavior of rat 9L glioma cells when subjected 
to various combinations of photon beam energy and percent thymidine replacement by IUdR. 
Because data for each combination was the result of multiple measured data sets (see Table 
3.11), a method of analysis was utilized to minimize the propagation of large systematic errors in 
the plating efficiency from biasing the errors in individual data points from a single measured 
data set. Also, a method was employed to isolate the effects of linear energy transfer, 
radiosensitization, and Auger electrons on the survival fraction versus dose curve. 
4.2 Methods & Materials 
4.2.1 Plotting the Cell Survival Curve & Chi-Squared Fit 
 The measured data points of SF ± σ versus D were plotted on a semi-log grid (linear in 
dose, logarithmic in surviving fraction), where each data point represented survival fraction from 
a single cell culture flask. Although plotted using a semi-log grid, the SF versus D curves were 
fit in linear space to the linear quadratic model:               
 
, where A, α and β were 
fitting parameters.  
 A weighted curve-fit was done by minimizing chi-squared, χ
2
, using the Sigma Plot
®
12 
(v 12.0) nonlinear curve-fitting algorithm. The Sigma Plot®12 nonlinear curve-fitting algorithm 




linear quadratic model that gave the best fit of the equation to the data. This algorithm seeks the 
values of the parameters that minimize χ
2
, the weighted sum of the squared differences between 
the values of the measured and calculated (or predicted) data; the weighting factor is σ
-2
, derived 
from the uncertainty σ for each data point. This process is iterative, repeating until the 
differences between the residual sum of squares decreases by less than a predetermined amount. 
This condition is known as convergence.  
4.2.2 Combining Data from Multiple Measured Data Sets for a Single Experimental Condition 
(E, %IUdR) 
 To achieve sufficient statistics to meaningfully quantify differences in the survival curves 
for differing experimental conditions (E, %IUdR), multiple sets of measured data (accrued on 
different dates) were required. In all cases, the plating efficiencies (average of “zero” dose 
points) varied amongst measured data sets as evident by large standard deviations (see Table 
3.13), and had large error bars ranging from 0.041 to 0.210. Therefore, normalizing each data 
point to the plating efficiency for its respective data set and then fitting all data sets together 
would propagate large systematic and random errors from the “zero” dose points to all other data 
points in the data set; furthermore, the data points would no longer be statistically independent. 
Additionally, some data sets had a small number of data points versus dose, hindering the fitting 
of that data to an individual survival curve. 
 Consequently, the following fitting scheme, illustrated in Figure 4.1, was utilized. First, 
the surviving fractions for all data points in a single data set j were normalized temporarily to the 
plating efficiency (average of “zero” dose points) for that data set. The plating efficiency’s 
uncertainty was ignored and not propagated into the error of the remaining survival fraction data 




%IUdR), including the “zero” dose points, were fit to the mathematical form of the survival 
curve by minimizing chi-squared for points in all multiple data sets simultaneously (see Equation 
(4.1)). Data points for each data set were then renormalized and re-fit to a final survival curve 
(see Equation (4.2)) that had a (SF, D = 0) = 1. 
4.2.2.1 First Curve Fit Routine 
 The purpose of the first curve fit routine was to identify outliers. The data for a single 
experimental condition (E, %IUdR), comprised of a total of R independent data sets, were fit to 
the linear quadratic model having a single value for α and β, but different normalizations (plating 
efficiencies), Aj, for each of the j data sets. This was accomplished within Sigma Plot®12 by 
doing a weighted least-squares fit of the data points (Di, SFi ± σi) with i = 1, N to the objective 
function:  
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(4.1) 
where: SFc(Di) = Calculated SF for the i
th
 data point,  
Di = Dose of the i
th
 data point, 




 δi,j = 1 if the i
th
 data point is part of the j
th
 measured data set,  
 Aj = Normalization parameter for the j
th
 measured data set,  
 α, β = Fit parameters for the survival curve for all N data points. 
Note that N is the total number of data points in R data sets with the same (E, %IUdR), i.e., 
  ∑   
 
   , where Nj is the total number of data points in the j
th
 measured data set.  
 After the first curve fit routine, outliers were identified (see Section 4.2.3) and removed 
from the data in preparation for the second curve fit. 
4.2.2.2 Second & Third Curve Fit Routines 
 The second curve fit routine, using the data set with outliers removed, determined new 
values for α, β and new normalization parameters (Aj). Then, the data points and error bars (SFi ± 
σi) within the j
th
 data set were renormalized by the factor (Aj)
-1
. Last, the renormalized composite 
data set was fit a third time to the function: 
   (  )     
          
 
  (4.2) 
If the renormalization procedure was done correctly, then A equaled unity and α, β remained the 
same as that resulting from the second curve fit routine. The purpose of the third curve fit routine 
was to check that renormalizations were done properly and to calculate the reduced chi-squared, 




   









   
  
(4.3) 
where ν = Number of degrees of freedom calculated by N –  3, 
 SFi(Di) = Measured SF for the i
th
 data point at dose Di,  
 σi = Uncertainty in SFi(Di),  




 To demonstrate this procedure, consider the data set listed in Table 4.1 for (25 keV, 0% 
IUdR), which contained 53 data points with no outliers for R = 3 measured data sets (40A, 40B, 
and 49 from Table 4.1). The data sets were fit simultaneously to Equation (4.1) using the 
weighted curve-fit algorithm in Sigma Plot®12. Figure 4.2(a)-(b) shows the results of this first 
fit with the colored lines representing the χ
2
 fit to the corresponding data points. The “zero” dose 
points (for each color) denote the fitted normalization constants (Aj); Aj values for data sets 40A, 
40B, and 49 were 0.8992, 0.7957, and 1.0773, respectively. The measured data sets, which 
contained no outliers, were then normalized by these constants and re-fitted using Equation (4.2). 
The final fit (Table 4.2(c)) yielded a normalization factor of unity (A = 1.000), as expected, and 
the values for α and β remained unchanged.  
Table 4.1: Curve-fitting information for experimental condition (25 keV, 0% IUdR). Table 
shows data (columns 2−4), fitting parameters (columns 5−8), theoretical “zero” dose point 
(column 9), and renormalized surviving fraction data and weighting factor (columns 10−12) for 
final fit to the R = 3 data sets.  
Data Set D i (Gy) SF i σSFi σSFi
-2 δi, j δi, j δi, j A j SF i *A j




j 40A 40B 49
9/8/2011 0.0 0.877 0.238 17.59 1 0 0 0.8992 0.975 0.265 14.23
(040A) 0.0 1.108 0.278 12.95 1 0 0 0.8992 1.232 0.309 10.47
0.0 1.015 0.262 14.53 1 0 0 0.8992 1.129 0.292 11.75
2.1 0.877 0.238 17.59 1 0 0 0.8992 0.975 0.265 14.23
2.1 0.600 0.188 28.29 1 0 0 0.8992 0.667 0.209 22.88
2.1 0.739 0.214 21.89 1 0 0 0.8992 0.821 0.238 17.71
4.3 0.417 0.144 48.20 1 0 0 0.8992 0.464 0.160 38.99
4.3 0.584 0.176 32.34 1 0 0 0.8992 0.649 0.196 26.16
4.2 0.292 0.118 72.35 1 0 0 0.8992 0.325 0.131 58.46
5.6 0.334 0.090 124.51 1 0 0 0.8992 0.371 0.100 100.71
5.6 0.375 0.096 108.86 1 0 0 0.8992 0.417 0.107 88.10
5.5 0.313 0.086 133.92 1 0 0 0.8992 0.348 0.096 108.31
8.2 0.042 0.021 2255.19 1 0 0 0.8992 0.046 0.023 1816.12
8.1 0.073 0.028 1270.70 1 0 0 0.8992 0.081 0.031 1023.99
8.0 0.125 0.037 724.39 1 0 0 0.8992 0.139 0.041 584.28
9.9 0.042 0.017 3382.78 1 0 0 0.8992 0.046 0.019 2733.08
9.7 0.028 0.014 5106.29 1 0 0 0.8992 0.031 0.016 4125.28






Table 4.1 (continued) 
Data Set D i (Gy) SF i σSFi σSFi
-2 δi, j δi, j δi, j A j SF i *A j




j 40A 40B 49
9/9/2011 0.0 0.857 0.245 16.63 0 1 0 0.7957 1.077 0.308 10.52
(040B) 0.0 1.095 0.289 11.94 0 1 0 0.7957 1.376 0.364 7.56
0.0 1.048 0.281 12.70 0 1 0 0.7957 1.317 0.353 8.03
2.0 0.524 0.179 31.09 0 1 0 0.7957 0.658 0.225 19.69
2.0 0.714 0.218 21.08 0 1 0 0.7957 0.898 0.274 13.35
2.0 0.667 0.208 23.02 0 1 0 0.7957 0.838 0.262 14.58
4.2 0.474 0.161 38.81 0 1 0 0.7957 0.596 0.202 24.58
4.2 0.238 0.113 77.94 0 1 0 0.7957 0.299 0.142 49.32
4.1 0.172 0.090 122.97 0 1 0 0.7957 0.217 0.113 77.81
5.6 0.474 0.114 77.62 0 1 0 0.7957 0.596 0.143 49.14
5.5 0.237 0.076 173.22 0 1 0 0.7957 0.298 0.096 109.60
6.4 0.259 0.080 157.13 0 1 0 0.7957 0.325 0.100 99.41
8.2 0.087 0.031 1016.00 0 1 0 0.7957 0.109 0.039 642.08
8.0 0.098 0.033 897.98 0 1 0 0.7957 0.123 0.042 567.48
7.9 0.054 0.025 1653.95 0 1 0 0.7957 0.068 0.031 1046.11
10.0 0.029 0.015 4734.70 0 1 0 0.7957 0.036 0.018 3010.99
9.8 0.043 0.018 3131.90 0 1 0 0.7957 0.054 0.022 1975.78
9.6 0.051 0.019 2674.08 0 1 0 0.7957 0.063 0.024 1699.54
10/21/2011 0.0 0.869 0.188 28.19 0 0 1 1.0773 0.807 0.175 32.70
(049) 0.0 1.178 0.231 18.72 0 0 1 1.0773 1.093 0.215 21.73
0.0 0.953 0.200 24.94 0 0 1 1.0773 0.885 0.186 28.95
10.1 0.060 0.014 5121.25 0 0 1 1.0773 0.056 0.013 5920.92
9.8 0.041 0.012 7557.70 0 0 1 1.0773 0.038 0.011 8775.05
9.6 0.057 0.014 5414.46 0 0 1 1.0773 0.053 0.013 6274.33
7.7 0.165 0.029 1217.16 0 0 1 1.0773 0.153 0.027 1408.90
7.6 0.170 0.029 1181.65 0 0 1 1.0773 0.157 0.027 1370.44
7.4 0.124 0.025 1655.85 0 0 1 1.0773 0.115 0.023 1917.68
5.7 0.294 0.053 350.93 0 0 1 1.0773 0.273 0.050 406.97
5.5 0.361 0.060 277.17 0 0 1 1.0773 0.335 0.056 321.29
3.9 0.712 0.150 44.51 0 0 1 1.0773 0.661 0.139 51.65
3.8 0.597 0.134 55.51 0 0 1 1.0773 0.554 0.125 64.44
3.8 0.643 0.141 50.61 0 0 1 1.0773 0.597 0.131 58.70
2.3 0.757 0.172 33.72 0 0 1 1.0773 0.703 0.160 39.14
2.2 0.617 0.151 43.69 0 0 1 1.0773 0.573 0.140 50.70





Figure 4.2: Example of fitting the measured data (R = 3) for (25 keV, 0% 
IUdR). (a) Fit for a single data set. (b) Individual simultaneously-fitted curves 
for the three data sets; the fitted values were α = 0.0863, β = 0.0239, A1 = 
0.8992, A2 = 0.7957, A3 = 1.0773, and χυ
2 
= 0.8947. (c) Final fitted curve for 
all renormalized data points; the final fit parameters were α = 0.0863, β = 







4.2.3 Removing Outliers 
 After data points of an experimental condition (E, %IUdR) underwent the first curve fit 
routine (Section 4.2.2.1), a threshold of 2.5 standard deviations (2.5σ), based on Chauvenet’s 
criterion (Bevington 1992), was imposed to determine whether a data point was an outlier, and 
thus eliminated from the data set before re-fitting the data to Equation (4.1). Sigma Plot®12 
generated the residuals:  
 
          




for each data point as part of the fit routine, making it convenient to determine how many 
standard deviations away a data point was from the fit. If the absolute value of the residual was 
larger than 2.5, then the data point was considered an outlier and was removed from the set of 
data points (see a subset of (25 keV, 9% IUdR) data points evaluated for outliers in Table 4.2).  




4.2.4 Determination of Sensitization Enhancement Ratios at 10% Survival  
 The sensitization enhancement ratio at 10% surviving fraction (SER10) was calculated for 
each experimental condition as the ratio of dose required to achieve 10% survival (D10) for cells 
under one (E, %IUdR) experimental condition to another, i.e., for cells without IUdR irradiated at 
4 MV to that of cells with DNA-incorporated IUdR irradiated at photon energy E. SER10,T(E, 
%IUdR) is the combined or total SER, which includes (1) the effect of enhanced cell killing 
caused by the linear energy transfer (LET) effect of keV photons, (2) the radiosensitization (RS) 
effect of IUdR, and (3) the Auger effect (AE) from IUdR. Assuming that the LET, RS, and AE 
effects are independent of each other, it has been assumed that the SER10,T(E, %IUdR) is the 
product of SER10,LET(E, %IUdR), SER10,RS(E, %IUdR), and SER10, AE(E, %IUdR). 
 
Table 4.2: Outlying data in experimental data set (25 keV, 9% IUdR). 
Column “Res > 2.5” evaluated the residuals (res) of each data point. If 
the absolute value of the residual was > 2.5, it was flagged with a “1”. 
Flagged data points (highlighted in red) were removed from data set j for 
that experimental condition, which was re-fit with Equation (4.1) to 
determine the final normalization constants, Aj. 
Data Set j D i (Gy) SF i σ SF i SFp Res Res > 2.5
(039) 0 1.129 0.236 0.7771 1.4925 0
0 0.802 0.187 0.7771 0.1330 0
0 1.069 0.227 0.7771 1.2878 0
2.2 0.763 0.165 0.6195 0.8717 0
2.2 0.689 0.154 0.6195 0.4519 0
2.1 0.664 0.151 0.6307 0.2247 0
3.4 0.633 0.113 0.4722 1.4253 0
3.4 0.383 0.083 0.4722 -1.0768 0
3.3 0.633 0.113 0.4849 1.3126 0
5.9 0.221 0.055 0.1919 0.5335 0
5.8 0.258 0.060 0.2007 0.9547 0
5.7 0.185 0.050 0.2097 -0.5010 0
7.3 0.052 0.020 0.0951 -2.2044 0
7.2 0.074 0.024 0.1005 -1.1295 0





Table 4.2 (continued) 
Data Set j D i (Gy) SF i σ SF i SFp Res Res > 2.5
9.2 0.011 0.007 0.0292 -2.5019 1
9 0.042 0.015 0.0335 0.5726 0
(041) 0 1.075 0.235 1.2306 -0.6612 0
0 0.991 0.221 1.2306 -1.0853 0
0 0.934 0.212 1.2306 -1.3985 0
1.7 1.189 0.252 1.0651 0.4896 0
1.7 0.934 0.212 1.0651 -0.6183 0
1.7 1.160 0.248 1.0651 0.3842 0
4.5 0.767 0.176 0.5320 1.3379 0
4.4 0.665 0.160 0.5507 0.7159 0
4.4 0.767 0.176 0.5507 1.2316 0
6.1 0.269 0.064 0.2773 -0.1354 0
6.1 0.345 0.075 0.2773 0.9122 0
6 0.230 0.059 0.2904 -1.0238 0
8.2 0.096 0.026 0.0890 0.2706 0
8 0.077 0.023 0.1005 -1.0443 0
7.9 0.134 0.031 0.1067 0.8961 0
9.9 0.055 0.016 0.0281 1.7439 0
9.7 0.060 0.016 0.0325 1.6676 0
10.4 0.064 0.017 0.0192 2.6469 1
(051) 0 1.255 0.319 0.8837 1.1615 0
0 0.982 0.272 0.8837 0.3604 0
0 0.764 0.233 0.8837 -0.5165 0
2 0.495 0.163 0.7296 -1.4416 0
2 0.630 0.188 0.7296 -0.5322 0
2 0.810 0.219 0.7296 0.3653 0
4.1 0.675 0.170 0.4368 1.4027 0
4.1 0.472 0.137 0.4368 0.2580 0
4 0.540 0.148 0.4509 0.5985 0
6.5 0.054 0.039 0.1644 -2.8628 1
6.4 0.243 0.085 0.1726 0.8292 0
6.3 0.297 0.095 0.1812 1.2234 0
8 0.095 0.037 0.0722 0.6329 0
7.8 0.082 0.034 0.0813 0.0144 0
8.8 0.068 0.031 0.0436 0.7971 0




 Each SER10 value results from the comparison of specific conditions for D10. SER10,T is 
given by reference to (4 MV, 0% IUdR):  
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(4.5) 
The values for D10 and their uncertainty were determined from the fitted survival curves and 
corresponding 95% confidence intervals. The uncertainties in D10 (±σ) were estimated as one-
quarter of the dose range spanned by the 95% confidence interval for the fits of the measured 
data to the linear quadratic model, which were calculated by SigmaPlot®12. The total dose range 
spanned by the 95% confidence interval represents 4σ (i.e., ± 2σ), so one-fourth of the 95% 
confidence interval equals one σ. 
 Separate SER10 values can be written for each effect: LET, RS, and AE. The SER10,LET 
compares D10 without IUdR for 4 MV to energy E: 
 
         (       )   
   (           )
   (         )
  
(4.6) 
The SER10,RS compares D10 at 4 MV with and without IUdR: 
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(4.7) 
Finally, the SER10,AE can be calculated from the other SER10 values by: 
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 To calculate SER10,AE(E, %IUdR), certain assumptions were made. Because SER10,LET(E, 
%IUdR) describes the impact that the quality of the radiation has on cell killing while 




SER10,RS for the experimental condition (4 MV, 0%IUdR) were defined as unity because these 
were the chosen reference conditions. Because there is no significant Auger effect elicited at 4 
MV since most interactions are governed by the Compton effect, SER10,AE(4 MV, %IUdR) was 
also considered to be unity. SER10,LET value is a result of the energy used for irradiation 
compared to 4 MV, so SER10,LET is the same for each energy, regardless of the concentration of 
IUdR present in the cells, i.e., SER10,LET(E, %IUdR) = SER10,LET(E, 0% IUdR). SER10,RS is a 
result of the %IUdR in the cells, independent of the energy used to irradiate them, i.e., 
SER10,RS(E, %IUdR) = SER10,RS(4 MV, %IUdR). 
 The uncertainties in Equations (4.5)−(4.8) were determined by propagating independent 
errors. For SER10,T(E, %IUdR): 
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For SER10,LET(E, % IUdR): 
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For SER10,RS(E, % IUdR): 
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Finally, for SER10,AE(E, % IUdR):  
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4.3.1 Analysis of 4 MV Data 
 The 4MV irradiations comprised the largest number of data sets.  The (4 MV, 0% IUdR) 
data served as the reference for all other experimental conditions. Figure 4.3(a)-(c) show the 
curve-fits for each level of %IUdR and Figure 4.3(d) compares the three curve-fits. The 
shoulders of the curves increasingly bend as the %IUdR increases, thus, decreasing the D10 
values.  
Table 4.3 and Table 4.4 report the survival curve results, including fit parameters, 
reduced chi-squared values, D10 values and SER10 values for the 4 MV irradiations at 0%, 9%, 
and 18% IUdR. Since (4 MV, 0% IUdR) is the reference experimental condition, by definition 
SER10,T(4 MV, 0% IUdR) = 1.00. Note that SER10,RS(E, 9% IUdR) = SER10,T(4 MV, 9% IUdR) = 
1.28 ± 0.02 and SER10,RS(E, 18% IUdR) = SER10,T(4 MV, 18% IUdR) = 1.40 ± 0.02, as a result 
of the radiosensitizing properties of IUdR.   
4.3.2 Analysis of 35 keV Data 
Experimental conditions (35 keV, %IUdR) were the most significant data sets in that 
these showed the greatest Auger effect, 35 keV being just above the K-edge of iodine. Figure 
4.4(a)-(c) show the curve-fits for each level of %IUdR and Figure 4.4(d) compares the three 
curve-fits. The shoulders of the curves disappear as the %IUdR increases, thus, decreasing the 
D10 values.  
Table 4.3 and Table 4.4 report the survival curve results, including fit parameters, 
reduced chi-squared values, D10 values and SER10 values for the 35 keV irradiations at 0%, 9%, 




Figure 4.3: Fits to cell survival data at 4 MV for 0%, 9%, and 18% IUdR. 
The black line represents the curve fit; blue lines represent the 95% 
confidence interval. Plot of (a) (4 MV, 0% IUdR) data from 148 data 
points, (b) (4 MV, 9% IUdR) data from 62 data points, and (c) (4 MV, 18% 
IUdR) data from 93 data points. (d) Comparison of resulting curve-fits for 








Figure 4.4: Fits to cell survival data at 35 keV for 0%, 9%, and 18% IUdR. 
The black line represents the curve fit; blue lines represent the 95% 
confidence interval. Plot of (a) (35 keV, 0% IUdR) data from 47 data points, 
(b) (35 keV, 9% IUdR) data from 83 data points, and (c) (35 keV, 18% IUdR) 
data from 62 data points. (d) Comparison of resulting curve-fits for 35 keV x-




0.03, reflects the therapeutic gain completely attributed to the higher relative biological effect 
(RBE) of the higher LET, lower energy electrons created by 35 keV photons as opposed to those 
of 4 MV x-rays. The values SER10,T(35 keV,  9% IUdR) = 1.41 ± 0.03 and SER10,T(35 keV,  18% 




IUdR) = 2.05 ± 0.04 are attributed to a combination of the LET effect, radiosensitization of 
IUdR, and the Auger effect. The Auger contributions to the sensitization enhancement ratio were 
calculated to be SER10,AE(35 keV, 9% IUdR) = 1.01 ± 0.04 and SER10,AE(35 keV, 18% IUdR) = 
1.35 ± 0.05. 
4.3.3 Analysis of 30 keV Data 
Experimental conditions (30 keV, %IUdR) were data that was designed to detect any 
Auger effect due to L-edge photoelectric interactions, as 30 keV is below the K-edge of iodine. 
Figure 4.5(a)-(b) show the curve-fits for each level of %IUdR and Figure 4.5(c) compares the 
two curve-fits. The shoulder of the 18% IUdR curve bent compared to the 0% IUdR curve, thus, 
decreasing its D10 value.  
Table 4.3 and Table 4.4 report the survival curve results, including fit parameters, 
reduced chi-squared values, D10 values and SER10 values for the 30 keV irradiations at 0% and 
18% IUdR. The value SER10%,T(30 keV, 0% IUdR) = SER10%,LET(30 keV, % IUdR) = 1.22 ± 
0.02, reflects the therapeutic gain completely attributed to the higher RBE of the lower energy, 
higher LET electrons created by 30 keV photons as opposed to those of 4 MV x-rays. The value 
SER10%,T(30 keV, 18% IUdR) = 1.82 ± 0.04 is attributed to a combination of the LET effect, 
radiosensitization of IUdR, and the Auger effect. The Auger contribution to the sensitization 
enhancement ratio was SER10,AE(30 keV, 18% IUdR) = 1.06 ± 0.03. 
4.3.4 Analysis of 25 keV Data 
Experimental conditions (25 keV, %IUdR) provided data that were designed to detect 
any Auger effect as a result of L-edge photoelectric interactions, as again 25 keV is below the K-




Figure 4.5: Fits to cell survival data at 30 keV for 0% and 18% IUdR. The 
black line represents the curve fit; blue lines represent the 95% confidence 
interval. Plot of (a) (30 keV, 0% IUdR) data from 97 data points and (b) 
(30 keV, 18% IUdR) data from 62 data points. (c) Comparison of resulting 




compares the three curve-fits. The curves for 0 and 9% IUdR somewhat overlap each other 
between 0 and ~7 Gy, hinting that 9% IUdR did not elicit a radiosensitizing effect in this dose 
range. At doses > 7 Gy, a small decrease in the curvature of the 9% IUdR curve was present. 
Comparing these two curves to that of 18% IUdR, the familiar bending in the shoulder of the 
curve is present with the increase of %IUdR, thus, decreasing the D10 value for 18% IUdR. 
Table 4.3 and Table 4.4 report the survival curve results, including fit parameters, 
reduced chi-squared, D10 values and SER10 values for the 25 keV irradiations at 0%, 9%, and 
18% IUdR. The value SER10%,T(25 keV, 0% IUdR) = SER10%,LET(25 keV,  0% IUdR) = 1.37 ± 
0.02, reflects the therapeutic gain completely attributed to the higher RBE of the lower energy, 
higher LET electrons created by 25 keV as opposed to those of 4 MV x-rays. The values 
SER10%,T(25 keV,  9% IUdR) = 1.44 ± 0.03 and SER10,T(25 keV, 18% IUdR) = 1.90 ± 0.04 were 





Figure 4.6: Fits to cell survival data at 25 keV for 0%, 9%, and 18% 
IUdR. The black line represents the curve fit; blue lines represent the 
95% confidence interval. Plot of (a) (25 keV, 0% IUdR) data from 53 
data points, (b) (25 keV, 9% IUdR) data from 50 data points, and (c) (25 
keV, 18% IUdR) data from 69 data points. (d) Comparison of resulting 




attributed to a combination of the LET effect and radiosensitization of IUdR. The Auger effect 
was SER10,AE(25 keV, 9% IUdR) = 0.82 ± 0.02 and SER10,AE(25 keV, 18% IUdR) = 0.98 ± 0.03.  




4.3.5 Summary of Results 
 Table 4.3 summarizes values for the α ± σα and β ± σβ parameters, where σα and σβ are 
standard errors, reduced chi-squared values, and D10 ± σD10 for all experimental conditions (E, 
%IUdR) resulting from chi-squared fitting the SF versus D data to            
 
for all 
combinations of energies (4 MV, 25 keV, 30 keV, 35 keV) and %IUdR (0%, 9%, 18%).  
Table 4.4 shows values for SER10(E, %IUdR) ± σ resulting from the calculated D10 
values, broken down into its LET, RS, and AE contributions.  
4.4 Discussion 
4.4.1 4 MV Survival Curves  
 The (4 MV, 0% IUdR) survival curve (D10 = 11.2 ± 0.08 Gy) is comparable to the 
radiation survival curve (D10 ≈ 10.8 Gy) of rat 9L glioma cells reported by Franko et al. (1992). 
This result builds confidence in the (4 MV, 0% IUdR) data as a reference for comparison to other 
experimental conditions tested in this project. 
4.4.2 The LET Effect of 25-35 keV Monochromatic X-Rays  
 Figure 4.7 plots the dose-survival curves and lists the SER10,LET values for cells without 
IUdR irradiated using 4 MV x-rays, and 35 keV, 30 keV and 25 keV. The RBE for rat 9L glioma 
cells increased as photon energy decreased (from 1.08 at 35 keV to 1.37 at 25 keV) due to the 
increased LET of electrons produced by low energy x-rays. Lower energy x-rays required less 
dose to achieve 90% cell killing than higher energy x-rays. Dugas et al. (2011) reported no LET 
effect for CHO cells. However, it is possible that their utilization of a less sophisticated curve 







Table 4.4: Summary of calculated SER10 values for all experimental 
conditions (E, %IUdR). The components of SER10,T (LET, RS, and AE 




0 11.2 ± 0.08 1.00 1.00 1.00 1.00
9 8.7 ± 0.11 1.28 ± 0.02 1.00 1.28 ± 0.02 1.00 ± 0.02
18 8.0 ± 0.08 1.40 ± 0.02 1.00 1.40 ± 0.02 1.00 ± 0.02
35 keV
0 10.4 ± 0.32 1.08 ± 0.03 1.08 ± 0.03 1.00 1.00 ± 0.04
9 8.0 ± 0.15 1.41 ± 0.03 1.08 ± 0.03 1.28 ± 0.02 1.01 ± 0.04
18 5.5 ± 0.11 2.05 ± 0.04 1.08 ± 0.03 1.40 ± 0.02 1.35 ± 0.05
30 keV
0 9.2 ± 0.11 1.22 ± 0.02 1.22 ± 0.02 1.00 1.00 ± 0.02
18 6.2 ± 0.13 1.82 ± 0.04 1.22 ± 0.02 1.40 ± 0.02 1.06 ± 0.03
25 keV
0 8.2 ± 0.12 1.37 ± 0.02 1.37 ± 0.02 1.00 1.00 ± 0.02
9 7.8 ± 0.16 1.44 ± 0.03 1.37 ± 0.02 1.28 ± 0.02 0.82 ± 0.02
18 5.9 ± 0.12 1.90 ± 0.04 1.37 ± 0.02 1.40 ± 0.02 0.98 ± 0.03
SER10,T SER10,LET SER10,RS SER10,AE
D10 ± σD10
(Gy)
Table 4.3: Summary of results for all experimental conditions (E, %IUdR). The number of data 
sets and data points, α and β parameters and their associated standard errors, D10 values and their 
associated standard errors, and reduced chi-squared values (χν
2
) are shown for each (E, %IUdR). 
Energy % IUdR R N Number of
Data Sets Data Points Outliers
4 MV 0% 13 148 2 0.0301 ± 0.0114 0.0155 ± 0.0010 0.9748 11.24 ± 0.08
9% 4 62 1 0.0417 ± 0.0203 0.0253 ± 0.0021 1.0788 8.75 ± 0.11
18% 5 93 2 0.0723 ± 0.0205 0.0269 ± 0.0019 0.8000 8.00 ± 0.08
35 keV 0% 6 47 1 0.1002 ± 0.0281 0.0118 ± 0.0033 0.4989 10.37 ± 0.32
9% 9 83 0 0.1727 ± 0.0218 0.0147 ± 0.0024 0.6450 7.95 ± 0.15
18% 7 62 0 0.3989 ± 0.0329 0.0040 ± 0.0051 0.6470 5.47 ± 0.11
30 keV 0% 6 97 1 0.0905 ± 0.0244 0.0172 ± 0.0025 0.7548 9.24 ± 0.11
18% 4 62 1 0.2172 ± 0.0380 0.0250 ± 0.0044 1.0195 6.19 ± 0.13
25 keV 0% 3 53 0 0.0863 ± 0.0367 0.0239 ± 0.0038 0.8584 8.18 ± 0.12
9% 4 50 4 0.0249 ± 0.0460 0.0346 ± 0.0053 1.1539 7.81 ± 0.16
18% 5 69 3 0.2250 ± 0.0409 0.0277 ± 0.0050 1.1273 5.92 ± 0.12
α ± σ α β ± σ β χ ν





The RBE values listed in Table 4.5 and plotted in Figure 4.8 (Spadinger & Palcic 1992, 
Hoshi et al. 1988, Nath et al. 1987, Bistrovic et al. 1986) were measured in different cell lines, 
such as Chinese hamster ovary (CHO), Chinese hamster fibroblast (V79), and Chinese hamster 
(CH) lung cells. Nonetheless, the trend of RBE values, which are influenced by many factors, 
including the radiosensitivity of the various cell lines, in general decreased with increasing 
effective energy (decreasing LET). The authors either reported an effective energy or a half-
value layer for their x-ray beams; for the half-value layers, effective energies were determined by 
interpolation using a table of attenuation coefficients (Hubbell & Seltzer 2004) for the 
attenuating material.  
 
 
Figure 4.7: Survival curves for rat 9L glioma cells with 0% IUdR. Irradiation energies 





Table 4.5: Comparison of RBE values as a function of effective energy for previously published 
cell irradiation data. Values highlighted are from the present study. 
Figure 4.8: Plot of RBE values as a function of effective energy (keV). Data were measured in 
previously published data (see Table 4.5), except the blue circles (this work’s data). The curve-
fit (f = 1 + 1.149*(Eeff - 8.000)
0.558




4.4.3 IUdR as a Radiosensitizer  
 Figure 4.9 shows the survival curves for 4 MV irradiated 9L cells containing 0%, 9%, 
and 18% IUdR. 9L cells experienced 28% and 40% increases in cell killing when they contained 
9% and 18% IUdR, respectively. 
 The SER10,RS for (4 MV, 9% IUdR) and (4MV, 18% IUdR) were 1.28 ± 0.02 and 1.40 ± 
0.02, respectively, compared to 1.5 ± 0.1 and 2.6 ± 0.1 for CHO cells with 9% and 17% IUdR, as 
reported in Dugas et al. (2011). The radiosensitization effect of IUdR was less in 9L cells than in 
CHO cells, possibly because 9L cells have superior capabilities to repair. Bencokova et al. 
(2008) observed via immunofluorescence that the DSB repair rate of 9L cells was fast and 
complete with all DSBs repaired in 15 hours after receiving a 2 Gy dose. 
Figure 4.9: Survival curves for 4 MV and 0%, 9%, and 18% IUdR. SER10,RS(4 MV, 




4.4.4 The Auger Effect  
 Table 4.6 lists SER10,T, SER10,LET, SER10,RS, and SER10,AE values for 35 keV irradiations 
for this work and extracted from Dugas et al. (2011). The SER10,T for 9L cells irradiated under 
the experimental conditions (35 keV, 9% IUdR) and (35 keV, 18% IUdR) were 1.41 ± 0.03 and 
2.05 ± 0.04, respectively, compared to 2.0 ± 0.1 and 4.1 ± 0.2 for CHO cells under the 
experimental conditions (35 keV, 9% IUdR) and (35 keV, 17% IUdR), respectively.  
  9L cells are more radioresistant at 35 keV compared to CHO cells, as demonstrated by 
smaller SER10,RS values. 9L cells did not experience a significant Auger effect at the 9% IUdR 
level, while CHO cells exhibited a therapeutic gain of 30% due to the Auger effect alone. At the 
18% IUdR level, 9L cells had therapeutic gain of 35% while at the 17% IUdR level, CHO cells 
had a 60% therapeutic gain due to Auger electrons. Clearly, the magnitude of the Auger effect 
depends on both cell line and amount of IUdR uptake. It is possible that the initial number of 
DSBs and repair mechanisms may be different between the two cells lines, a potential area for 
further investigation.  
 At 18% IUdR for 30 keV and 25 keV, respectively, approximately 3.9 and 4.5 
photoelectric events per 2 Gy dose were expected as compared to 20.1 at 35 keV according to 
Karnas et al. (2001) (see Table 1.4). To first order, assume that the expected SER10,AE = 1 + x, 
where x is proportional to the number of photoelectric events at the D10 dose level, i.e.,: 
Table 4.6: Comparison of SER10 values for rat 9L glioma and CHO cells, irradiated at 35 keV 
energy. CHO data is from Dugas et al. (2011). 
9% IUdR 18% IUdR 9% IUdR 17% IUdR
SER10,T (35 keV, %IUdR) 1.40±0.03 2.03±0.04 2.0±0.1 4.1±0.2
SER10,LET(35 keV, %IUdR) 1.07±0.03 1.07±0.03 1.0 1.0
SER10,RS(35 keV, %IUdR) 1.28±0.02 1.40±0.02 1.5±0.1 2.6±0.1
SER10,AE(35 keV, %IUdR) 1.01±0.04 1.35±0.05 1.3±0.1 1.6±0.1
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(m stands for “measured”). Hence, the expected SER10,AE were estimated to be approximately 
1.08 for either 30 keV or 25 keV. Data showed SER10,AE(30 keV, 18%) = 1.06 ± 0.03 and 
SER10,AE(25 keV, 18% IUdR) = 0.98. The result at 30 keV is consistent, however, the result at 25 
keV is somewhat inconsistent with expectations for which there is no apparent explanation. 
Systematic errors in the dosimetry cannot be the cause for this inconsistency since they would 
divide out in Equation (4.8). 
 Using a similar analysis as in Equation (4.13) for 9% IUdR, SER10,AE values of 1.26 and 
1.06 would be expected at 35 keV and 25 keV, respectively. However, values of 1.01 ± 0.04 and 
0.82 ± 0.02, respectively, were observed. Although significantly different, their ratios of 1.19 
(1.26/1.06) and 1.23 (1.01/0.82) are similar. 
 At 35 keV, an SER10,AE(18% IUdR) value of 1.35 ± 0.05 was observed. Although lower 
than what was observed for CHO by Dugas et al. (2011), it is equally important since the 
radiosensitization effect is less in 9L cells compared to CHO cells. At the 9% IUdR level, the 
expected SER10,AE for 35 keV was estimated to first order to be 1.18: 
       [       (               )   ] 
       (      )        
(4.14) 
Hence, the measured SER10,AE(35 keV, 9% IUdR) value of 1.01 ± 0.04 is less than what was 
expected. Of question is whether the value of SER10,RS (35 keV, 9% IUdR) = 1.28 ± 0.02 is too 
high, masking the Auger effect. 
 The results of 0% and 18% IUdR in 9L cells at 30 keV and 35 keV can be compared with 




comparison slightly below and above the K-edge of iodine (33.2 keV). The SER10 values, 
computed as: 
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(4.15) 
for energies 30 keV and 35 keV are 1.48 ± 0.04 and 1.89 ± 0.07, respectively. The SER10 ratio of 
35 keV: 30keV is 1.28 ± 0.06, which compares well with Corde’s et al. SER10 ratio of 1.31 
(SER10 values of 1.25 and 1.64 for 32.8 keV and 33.5 keV, respectively). 
 Corde’s et al. survival curves with 0% IUdR have a shoulder at 50 keV and 70 keV, as 
expected, however, show no shoulder at 32.8 keV and 33.5 keV where expected, nor for 10-20% 
IUdR at 32.8 keV where expected (see Figure 1.10). Contrastingly, this work’s survival curves at 
(35 keV, 0% IUdR), (30 keV, 0% IUdR), and (30 keV, 18% IUdR) all show shoulders. 
Furthermore, there is no reason to expect the SER10 values at 50 keV (2.62) to be greater than 
that at 33.5 keV (1.64) as reported in Corde et al., because Karnas et al. (2001) calculated fewer 
photoelectric events at 50 keV (13.3) than at 33.2 keV (20.8). Therein lies the need to either 
confirm or refute Corde’s et al. data from 40-70 keV. 
 An alternative to the SER10,AE calculation shown in Equation (4.8) is to calculate the ratio 
of  D10 values for an energy slightly above and below the K-edge, which is the more common 
method of calculating SER10,AE values (Laster et al. 1993). This method can be applied to the 
present results provided the difference in the LET effect between 35 keV and 30 keV photons is 
incorporated. Using this alternate method, at (35 keV, 18% IUdR): 
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Similarly, at (35 keV, 9% IUdR): 
       (              )   
   (              )
   (              )
 
         (      )
         (      )
  
                                                       
   (              )
   (              )
 
   (              )
   (              )
  
                       (
    
    
)  (
     
    
)              (4.17) 
As previously, any systematic dosimetric error in the 30 keV or 35 keV dosimetry divide out in 
Equations (4.16) and (4.17). It is not clear why these values for 18% and 9% IUdR are so close; 
however, it could be a statistical variation, i.e., values of 1.33 and 1.19 (one sigma larger and 
smaller for Equations (4.16) and (4.17), respectively) would not be unreasonable. 
 The 1.27 ± 0.06 value for (35 keV, 18% IUdR) is slightly different than the 1.35 ± 0.05 
value determined using Equation (4.8), but the 1.25 ± 0.06 value for (35 keV, 9% IUdR) is 
significantly different from the 1.01 ± 0.04 value determined using Equation (4.8). The smaller 
Auger effect at the 18% IUdR level calculated by Equation (4.16) might be partially explained 
due to the fact that contributions from L-edge Auger electrons by 30 keV photons are not being 
considered whereas in the thesis method, i.e., Equation (4.8), the effect from Auger electrons 
from all shells (K-, L-, M-,...) are considered. The large discrepancy at the 9% IUdR level might 
be explained by some systematic error in measuring the radiosensitization effect in this work. A 
SER10,AE(35 keV, 9% IUdR) value larger than 1.01 was expected to be measured, e.g., 
approximately 1.18 or half of the enhancement for 18% IUdR. Results using Equation (4.17) 
give further reason to suspect a systematic error was made in measuring SER10,RS(E, 9% IUdR), 




CHAPTER 5: CONCLUSIONS & RECOMMENDATIONS 
5.1 Summary of Results 
 Rat 9L Glioma Cell Survival: The survival curve for rat 9L glioma cells for the experimental 
condition (4 MV, 0% IUdR) resulted in a D10 value of 11.2 Gy, which compared well to 
previously reported data (Franko et al. 1992). This provided confidence in the measurements 
of dose and cell survival. 
 LET Effect: The SER10,LET of monochromatic x-ray beams (25-35 keV) increased from 1.08 
± 0.03 at 35 keV to 1.37 ± 0.02 at 25 keV. This was due to decreasing x-ray energy, resulting 
in lower-energy secondary electrons whose LET increased, hence increasing SER10,LET (i.e., 
RBE). These results were consistent with the trend of previously reported RBEs. 
 Radiosensitization Effect: The radiosensitivity of rat 9L glioma cells for 4 MV x-rays 
increased as %IUdR content in the DNA increased, being 1.28 ± 0.02 for 9% and 1.40 ± 0.02 
for 18%. The effect, however, was less than that reported in CHO cells (Dugas et al. 2011), 
i.e., about one-third the increase in SER10 per %IUdR. 
 Auger Effect (18% IUdR): At 35 keV, SER10,AE = 1.35 ± 0.05 was extracted; however, an 
alternative, more traditional analysis yielded 1.27 ± 0.06. Although lower than SER10,AE 
values extracted from Dugas et al. (2011) for CHO cells, it was equally significant since the 
radiosensitization effect was less in rat 9L glioma cells compared to CHO cells. 
Based on the number of photoelectric events per 2 Gy calculated by Karnas et al. (2001), 
the resulting SER10,AE value for 18% IUdR at 30 keV (1.06 ± 0.03) was consistent and at 25 
keV (0.98 ± 0.03) was somewhat inconsistent with what might be expected. It was not clear 




monochromatic x-ray dosimetry could not be the cause, as such errors divide out in Equation 
(4.8).  
 Auger Effect (9%): At 35 keV the extracted effect (SER10,AE = 1.01 ± 0.04) was less than 
what was expected (1.18); however, an alternative, more traditional analysis yielded 1.25 ± 
0.06. Of question was whether the value of SER10,RS (35 keV, 9% IUdR) = 1.28 ± 0.02 was 
too high, masking extraction of the Auger effect in the first method of analysis. No 
significant effect was expected or observed for 25 keV. In fact, the value of SER10,RS (25 
keV, 9% IUdR) = 0.82 ± 0.02 also indicated possible systematic errors in SER10,RS. 
 Dosimetry: Although random errors were less significant, there is the potential for systematic 
errors in the dosimetry. At 4 MV, dose values determined using calculated dose according to 
a clinical paradigm overestimated measured film dose by approximately 6%; if film doses 
were utilized, SER10,LET values would have decreased, but had no effect on SER10,RS or 
SER10,AE. 
  For 25-35 keV, the dosimetry was based on film that was calibrated to ion chamber 
dosimetry based on TG-61, which was slightly outside its intended scope. Also, the ion 
chamber was not calibrated at energies sufficiently low as to bracket the energies used in this 
study. Therefore, chamber factors had to be extrapolated. When compared with fluence 
measurements (converted to dose using MCNP5 Monte Carlo calculations) the ion chamber 
dose overestimated fluence-based dose by 2-7% at 25 keV and underestimated fluence-based 
dose by 1-2.5% at 35 keV. Again, systematic dose errors only impact SER10,LET, having no 
effect on SER10,AE. 
 Comparison with Corde’s et al. (2004) Data: With respect to the ratio of SER10 values 




was comparable to that of Corde et al. (2004) for SQ20B cells with ~10−20% IUdR 
irradiated at 33.5 keV and 32.8 keV (1.31). However, our survival curves for (35 keV, 0% 
IUdR), (30 keV, 0% IUdR), and (30 keV, 18% IUdR) all had shoulders as expected, whereas 
the corresponding curves of Corde’s et al. did not. Based on this comparison and this work’s 
accurate measurement of %IUdR in 9L cells, it is believed that this work’s data is of higher 
quality. Also, it is believed that this work’s method of combining multiple data sets for data 
analysis to be superior. 
5.2 Conclusions 
 The hypothesis of this thesis was that the SER10 for 9% and 18% IUdR-laden rat 9L 
glioma cells irradiated by 25-35 keV photons will be greatest at 35 keV due to the Auger effect. 
Results of this research proved the hypothesis to be correct; in fact, 35 keV was the only energy 
to exhibit any significant Auger effect. The effect, however, was only evident for cells 
containing 18% IUdR and marginal for cells containing 9% IUdR. Based on these results, the 
energy dependence of photo-activated Auger electron therapy from 40-70 keV remains of 
possible clinical relevance and is worth further investigation. 
5.3 Recommendations for Improved Technology & Methodology in Future Cell Survival 
Measurements 
 Future monochromatic x-ray measurements should be of higher quality on the new 
medical radiobiological beamline at CAMD, which will have several enhancements to the 
present study. A comparison of some of the properties of the new beamline expected to be 
operational in late 2013 is summarized in Table 5.1.  
 Beam monitor: The x-ray beam intensity should be monitored using the current measured 




current as a function of irradiation time that was used in this study. It should be able to 
automatically integrate and record the ion chamber current (proportional to photon fluence 
and dose rate) readings so that the user no longer needs to manually record the ring current 
every five minutes and keep time of the irradiation. This is particularly important because 
previous data from Brown et al. (2012b) showed the ratio of dose rate to ring current varied 
for at least one hour after electron injection. 
 4 MV Irradiations: The objective is to make the 4 MV dose received by the cells less 
subjective to errors with respect to depth and to achieve agreement between calculated and 
film measured dose given to the cells. Irradiations at 4 MV should be done at a depth of at 
least 2 cm to provide sufficient build-up of secondary electrons and to maintain full scatter 
conditions. This can be accomplished by using a 30 x 30 cm
2 
field, milling the shapes of four 
cell culture flasks into a 5 cm thick plastic water slab, and placing a 1 cm thick plastic water 
slab to cover the cell culture flasks. The air gap in the cell culture flask should also be 
eliminated by completely filling it with medium. To prevent medium spillage from the cell 
CAMD Old Beam New Beam Impact of New Beam Properties
Beamline Properties Properties
Improvements
Higher Up to 35 keV Up to 75 keV Investigate Auger effect at
Beam Energies higher energies (35-75 keV)
Increased D' << 0.1 Gy*min-1 D' > 0.1 Gy*min-1 Reduced radiation times at
Monochromatic at E > 35 keV at E < 75 keV E > 35 keV
Photon Flux
Increased 3 cm 10 cm More cell cultures irradiated
Beam Width at the same time; small animal 
irradiation studies possible
Beam Monitor Ring current * duration Transmission Increase efficiency and
of irradiation ion chamber accuracy of delivered dose





culture flasks, the phantom can be positioned vertically such that the flasks are pointed 
upward and the gantry of the linac can be rotated 90
o to maintain the same geometry as in 
this project. 
 Monochromatic keV Photon Irradiations: Monochromatic irradiations should also be done at 
a deeper depth. The objective is to make the cell dose less sensitive to variations in dose in 
the first 1 cm depth as observed by Oves (2008). The shape of a cell culture tube flask could 
be milled into a PMMA block such that the flask could be inserted into the phantom and the 
distance from the surface of the phantom to the cells be approximately 1.2 cm. Also, it 
should be possible to use film as an in vitro dosimeter to periodically measure the dose rate 
throughout an electron injection cycle as well as at the beginning and/or at the end of a cell 
irradiation experiment. As a minimum, the dose to the cells should be measured with film at 
the beginning, middle, and end of each re-injection cycle to document no change.  
5.4 Recommendations for Future Cell Survival Studies to Elucidate the Role of the Auger Effect 
in keV Irradiations 
 The present study was part of a larger study to understand the dependence of cell survival 
versus dose on the quality of the beam (i.e., energy of monochromatic x-rays). This requires 
additional data and radiobiological modeling. 
 Cell Irradiations (40−70 keV): Cell irradiations should be done at energies higher than 35 
keV (40−70 keV) to observe whether there is an optimal irradiation energy above the K-edge 
of iodine, as Corde et al. (2004) reported. An initial measurement of the cell survival curve at 





 Radiobiological modeling: Create a radiobiological model that includes the effects of (1) 
RBE of beam as a function of energy; (2) the number of photoelectric (i.e. Auger) events as a 
function of dose, %IUdR, and energy; and (3) radiosensitivity as a function of dose, %IUdR, 
and energy. Then, all sets from all experimental conditions (E, %IUdR) should be fit at once. 
 % IUdR: 9L glioma cells should be allowed to uptake a concentration of IUdR that have 
additional values between 0% and 18% IUdR to evaluate the possibility of a threshold 
amount existing. It should also be investigated why there are such unusual results at 9% 
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APPENDIX A: CALCULATIONS 
A.1 Calculation of Photoelectric Interactions per 2 Gy Dose 
A.1.1 Calculation for the Number of Auger Events per 2 Gy Dose to Water for Iodine Atoms  
Step 1:  Calculating photoelectric cross section, σ, for iodine at 33.2 keV: 










) = mass attenuation coefficient = 35 cm2/g, assuming all photoelectric absorption at 
33.2 keV for iodine (Hubbell & Seltzer 2004). 
MI = molar mass of iodine = 126.9 g/mol. 
NA = Avogadro’s number = 6.023 x 10
23
 iodine atoms/mole. 








Step 2: Calculating photon fluence per Gy dose in water: 
Fluence,   = 
                   
    
. 
Energy fluence, Ψ = φ*E, where E = energy per photon = 33.2 keV. 
Dw = Ψ*(
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Step 3: Calculating number of photoelectric interactions per atom per Gy: 
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Step 4: Calculating number of photoelectric interactions in iodine per cell per 2 Gy (with 20% 
IUdR): 
There are 6 x 10
9 
base pairs (bps) of DNA per cell (Annunziato 2008). 
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A.1.2  Number of Auger Events per 2 Gy Dose to Water for Platinum  
This calculation follows the same steps 1−4 as in Section A.1.1: 
Step 1:  Calculating photoelectric cross section for platinum at 78.4 keV: 










) = mass attenuation coefficient = 8.981 cm2/g, assuming all photoelectric absorption at 
78.4 keV for platinum (Hubbell & Seltzer 2004). 
MPt = molar mass of platinum = 195.084 g/mol. 
NA = Avogadro’s number = 6.023 x 10
23
 platinum atoms/mole. 
                                                 
‡
 Agrees well with Humm & Charlton (1989). 
§










= 2909 barns/atom. 
 
Step 2:  Calculating photon fluence per Gy dose in water: 
Fluence,   = 
                   
    
. 
Energy fluence, Ψ = φ*E, where E = energy per photon = 78.4 keV. 
Dw = Ψ*(
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)   
Dw is dose to water. 
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) = mass energy absorption coefficient for medium, i.e. water = 0.02644 cm2/g for 78.4 
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= 3.011 x 10
12  
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Step 3: Calculating number of photoelectric interactions per atom per Gy: 
 
  
     8.7587 x 10-9  
            




Step 4: Calculating number of photoelectric interactions in platinum per cell per 2 Gy: 
According to Corde et al. (2002) they achieved a platinum content of 4.5 x 10
6 
atoms/cell for 
cells exposed to 1 μM CDDP for 12 h (17% cell survival), so: 
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) *  8.7587 x 10-9  
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A.2 Steps to Calculate the Dose Rate from Calibration Geometry to Cell Irradiation Geometry 
for 4 MV X-Rays 
(1) Professional medical physicists at MBPCC have calibrated the Clinac 21EX to deliver a dose 
rate at calibration point (FS = 10 x 10 cm
2
 (isocenter), SSD = 90 cm, do = 10 cm, SPDo = 
SSD + do = 100 cm) of 0.758 cGy*MU
-1
 to water at isocenter for 4 MV beam (  
 =   
     (10, 
10) = 0.758 cGy*MU
-1
). This dose rate can be used to calculate the dose rate for the cell 
irradiation geometry illustrated in Figure 3.1 (FS = 44.96 x 44.96 cm
2
, SPD = 149.88 cm, d = 
0.62 cm). Figure A.1 demonstrates step by step the geometry of the calculations required. 




) SSD SPD depth
(at SSD) (at SPD) (cm) (cm) (cm)
(1) H2O - 10 x 10 90 100 10
(2) H2O - 30 x 30 90 100 10
(3) H2O - 30 x 30 98.8 100 1.2
(4) Air 29.64 x 29.64 - 98.8 100 -
(5) Air - 44.96 x 44.96 - 149.88 -
(6) H2O - 44.96 x 44.96 - 149.88 1.2
(7) H2O - 44.96 x 44.96 - 149.88 0.62
Figure A.1: Diagram demonstrating steps to calculate the dose rate from calibration geometry 




(2) Using Table 3.1(b) (Section 3.2.1.1), the in-air output factors at depth = 10 cm due to both 
collimator and phantom scatter (Sc*Sp) can be looked up for a FS = 30 x 30 cm
2
 (let rc = 30 
cm) at calibration point (field size at isocenter, i.e., SPDo = 100 cm, for cell geometry is FS = 
30 x 30 cm
2
): 
                 
      
     (  )           (A.1) 
To calculate the dose rate to water using FS = 30 x 30 cm
2
 (isocenter) at calibration point 
(d = 10 cm),   
     (30, 10), Sc*Sp for the different field size must be considered and be 
multiplied to   
     (10, 10): 
            
     (     )     
     (     )       (  ) 
                                       
(A.2) 
(3) Now the depth in phantom is changed to a reference depth of dm = 1.2 cm (the depth of 
maximum dose), while maintaining the same source to point distance of 100 cm, so SSD = 
100 cm - 1.2 cm = 98.8 cm. The dose rate to water at a depth of 1.2 cm can be calculated 
using Equation (A.2), the tissue phantom ratio (TPR) for FS = 30 x 30 cm
2
 (isocenter) and dm 
= 1.2 cm, which can be interpolated using data from Table 3.1(a): 
            (      )         (A.3) 
   
     (      )     
     (     )     (      ) 
                                          
(A.4) 
(4) To convert   
     (30, 1.2) →   
     (30, 1.2) (dose rate in water to dose rate in air), the total 
scatter caused by the phantom must be removed from the value. This is accomplished by 
dividing out the peak scatter factor, PSF, from   
     (30, 1.2). Since FS = 30 x 30 cm
2 
at 
isocenter (100 cm), and dm = 1.2 cm, the top of the phantom is located at SSD = 98.8 cm. The 
field size at SSD = 98.8 cm is FS = 29.6 x 29.6 cm
2 
(let rdm = 29.6 cm). The true PSF is not 
known, but the normalized PSF was measured by Aird et al. (1996) and for a certain energy 
it varies by field size. The NPSF can be interpolated using a table found in Aird et al. (1996): 
         (    )          (A.5) 
The NPSF for a different field size will be required in step 7 and the ratio of the two NPSF 
will cancel the normalization constant, leaving the ratio of the true PSFs: 
            (   )
    (   )
 
   (   )






For the moment, however, the NPSF will be used instead of PSF to calculate   
     (30, 1.2): 
            
  
     (      )   
  
     (      )
    (    )
 
 
               
      
                  
(A.7) 
(5) Because the cell irradiation geometry has a SPD = 149.88 cm (150 cm from source to Solid 
Water® phantom surface where the cell flasks rest minus 0.12 cm thickness of the bottom of 
the cell flask) and FS = 45 cm at 150 cm, the field size at SPD = 149.88 cm is FS = 44.96 x 
44.96 cm
2
 (let r = 44.96 cm). To calculate the dose rate to air for FS = 44.96 x 44.96 cm
2
, the 
inverse square law must be taken into account for intensity lost at a larger SPD compared to 
intensity that occurs at isocenter (SPDo = 100 cm). The inverse square factor, ISF, is: 
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        .   (A.8) 
Therefore, 
   
 (         )     
     (      )      
                                         
(A.9) 
 (6) To convert the dose rate to air in Equation (A.9) to dose rate to water, the PSF needs to be 
factored back in, but for the larger field size (FS = 44.96 x 44.96 cm
2
). Extrapolating using 
the data found in Aird et al. (1996): 
                                                  (     )         (A.10) 
          
 (         )    
 (         )      (     ) 
                                        
(A.11) 
(7) Next, the depth of measurement for cell irradiations must be considered. The depth of the 
medium is 0.5 cm. The thickness of the top of the cell flask is 0.12 cm. Consider that as the 
top of cell flask extends outward and approaches infinity, where there would be electron and 
photon side scatter equilibrium, the total depth of measurement is approximated to be (0.5 + 
0.12) cm = 0.62 cm (let d = 0.62 cm), assuming the small air gap (≈ 0.5 cm) in between the 
top of the flask and the surface of the medium is ignored. The approximation still holds true 
if the width of the flask is much larger than the air gap in the flask (w>>ag). Because w = 5 





With this in mind, the dose rate to water for a field size FS = 44.96 x 44.96 cm
2
 and d = 0.62 
cm can be calculated using Equation (A.11) and TPR values from Table 3.1 (a). To know the 
fraction of the beam that contributes to dose at d = 0.62 cm, the TPRs for the desired depth, 
d, and dm are used: 
                               (          )
   (         )
 
 
      
     
         
(A.12) 
        Therefore,                     
 
  
 (          )     
 (         )  
   (          )
   (         )
 
                                         
(A.13) 
Finally, by combining steps 1-7 into a single equation, the dose rate value calculated in 
Equation (A.13) could be calculated using: 
 
     
    (  )    (  )     (     )  
    ( )
    (   )
     
   (   )
   (    )
  (A.14) 
Applying Equation (A.6): 
 
     
    (  )    (  )     (     )  
   ( )
   (   )
     
   (   )
   (    )
  (A.15) 
  
Figure A.2: Cell flask dimension approximation. When w >> ag ϶ w → ∞, the small 
air gap between the top of the cell flask and the surface of the medium can be ignored 
so that the total depth the 4 MV x-ray beam penetrates is 0.62 cm. This 
approximation still holds true in the present case because the width of the flask (5 cm) 




APPENDIX B: DNA ISOLATION PROTOCOL 
 
Details for DNA isolation using Promega Wizard kit Cat # A1120.  
 
Day 1 – Process I 
 
1. Pour a small amount of all reagents to be used into clean tubes to prevent contamination of 
reagents.  
 
2. Remove the medium from T25 flasks by decanting and using pipetor to get the last drops, 
three flasks at a time. Can use the same tip; keep caps on the flasks as much as possible, at all 
times. 
 
3. Pour PBS (1x strength) into a clean glass beaker and pour into flasks, three at a time (about 5 
mL). Turn flasks growth-side-up to avoid directly pouring on cells. Wash 2x with PBS. Pipet 
out last drops out each flask each time, especially before adding lysis solution. 
 
4. Add 600 μL of Nuclei Lysis Solution, three flasks at time and swirl it around gently. Place 
flasks flat as for growth for 5-10 minutes, then lie on its side on tilted angle for a few minutes 
so that the lysis solution pools at a corner of the flask. Remove solution using pipetor and 
transfer to microfuge tube (1.5-2 mL capacity; preferably clear-colored tubes). Pipet solution 
up and down before transferring to avoid mucus-like strings. 
 
5. Add 5 μL of RNAse Solution to the nuclear lysates and mix the samples by inverting the tube 
2-5 times. 
 
6. Incubate for 15-30 minutes in water bath at 37oC (optimally, 20 minutes).  
 
7. Remove samples from water bath and allow cooling to room temperature for 5-10 minutes 
before proceeding to step 8. Prepare ice water bath. 
 
8. To the room temp samples add 200 μL Protein Precipitation Solution. Vortex vigorously at 
high speed for 20 sec (to vortex correctly, watch to insure that there is a vortex within each 
tube; results should look like milk shake). Chill on ice bath for 5-15 minutes. 
 
9. Place tubes in same orientation each time to localize pellet. Centrifuge for 2 minutes at 13000-
16000x g. Place in ice bath for 5 minutes and centrifuge again for another 3 minutes. (In the 
meantime, prep for step 10; if large experiment, do samples in batches, with replacement on 
ice between runs. The precipitated protein will form a tight white pellet). Let sit in incubator 
for 1 min then place back in ice bath for ~ 2-3 minutes. 
 
10. Label new set of microfuge tubes and add 600 μL of isopropanol at room temperature. 
Carefully remove 600 μL of the supernatant containing the DNA and transfer to the new tubes 





11. Gently mix the solution by inversion for about 14 times or until white thread-like strands of 
DNA form. Stop at this point. Place samples in the fridge overnight without centrifuging. 
 
Day 2 – Process II 
 
12. Next day, centrifuge samples for 2 minutes, place on ice bath for 5 minutes, centrifuge for 2 
more minutes. The DNA will be visible as a small white pellet. 
 
13. Carefully decant the supernatant.  
 
14. Add 600 μL of room temperature 70 % ethanol and gently invert the tube several times to 
wash the DNA. Centrifuge for 2 minutes at room temperature. (To prepare EtOH, add 15 mL 
of DD H20 to 35 mL absolute ethanol). Place back in ice bath, 5 minutes; then centrifuge for 
2 minutes. 
 
15. Carefully aspirate ethanol using the 100 μL pipetor. The DNA pellet is very loose and care 
must be taken to avoid aspirating it. 
 
16. Invert tubes on clean absorbent paper and air-dry the pellets for at least 10-15 minutes. 
 






APPENDIX C: DOSIMETRY 
C.1 Radiochromic Film Dosimetry 
 
C.1.1 Film Calibration at 4 MV   
 The method for calibrating film at 4 MV is described in Brown et al. (2012a). Briefly, a 
total of twelve 5 x 5 cm
2 
pieces of EBT film were irradiated individually on two separate 
occasions with doses between 0.5−7 Gy to create a calibration curve (NOD vs. dose) that was 
fitted with a logarithmic function of the form recommended by the manufacturer: 
 
        (
     
   
)  
(C.1) 
where D is dose and a and b are constants, and fitted to the data using a nonlinear least squares 
algorithm in Gnuplot v4.4. Each piece of film was positioned at the center axis at 90 SSD with a 
30 x 30 cm
2
 field (defined at isocenter) and under a 10 cm thick slab of Solid Water
® 
phantom. 
The MUs to be delivered to the film were determined using standard monitor unit calculations 
based on dose output calibrated at 100 cm SSD following TG-51 protocol (Almond et al. 1999), 
as described in Section 3.2.1.3. X-ray dose output constancy from the linear accelerator was 
checked by professional medical physicists in accordance with TG-40 protocol (Kutcher et al.  
1994). Film readout and analysis will be discussed in Section C.1.3. 
C.1.2 Film Calibration for Monochromatic X-Rays   
 The method for calibrating film at 25, 30, and 35 keV are described in Brown et al. 
(2012a). For each calibration, 5 x 5 cm
2
 pieces of film were cut from a single sheet with a small 
line drawn on each piece to indicate the orientation of the original sheet. This was done to ensure 
consistent film orientation on the flatbed scanner, as discussed in Section C.1.3. Two pieces of 





 Ion chamber measurements were used to determine the dose delivered by the 
monochromatic beams at different depths in the PMMA phantom. To verify these ion chamber 
measurements, dose-response measurements were performed by irradiating eight pieces of film 
within the phantom at depths from 0.58 to 8.5 cm. The PMMA phantom was composed of 0.63 
and 1.27 cm thick 10 x 10 cm
2 
slabs, and the film pieces were sandwiched between theses slabs 
for irradiation. Each film piece was centered laterally and taped to an adjacent slab. The slabs 
were then aligned and taped together to minimize the effect of air gaps in the phantom. EBT film 
pieces were irradiated at each depth individually, while each set of EBT2 films were irradiated at 
all depths simultaneously. The front surface of each piece of film was used as the effective point 
of measurement (film thickness < 0.3 mm), and the depth values were determined accordingly. 
Small depth corrections (< 0.2 mm) to the EBT2 film depths were made to account for the 
presence of film pieces at shallower depths in the phantom by calculating the increased beam 
attenuation. These depth corrections are included in the range of depths given above. The 
duration of each irradiation was chosen so that a dose of approximately 2 Gy was delivered at a 
depth of 0.6 cm. The time and average ring current for each film irradiation were used to 
renormalize the measured ion chamber dose output. For each energy, Equation C.1 was fitted to 
the data. The reproducibility of this calibration method was tested by repeating the calibrations 
of EBT and EBT2 films. The dose-response curve was measured three times at 35 keV for EBT 
film and twice at 25 and 35 keV for EBT2 film. A new set of ion chamber measurements was 
made for each calibration. Film readout and analysis will be discussed in the next section. 
C.1.3 Film Readout and Analysis  
 Film analyses were done in the manner described in Brown et al. (2012a). All irradiated 




Corporation, Nagano, Japan) at least 24 hours after irradiation as recommended in the TG-55 
protocol (Niroomand-Rad et al. 1998). To avoid systematic errors arising from film handling, 
each piece of film was cleaned with a 70% ethanol solution prior to scanning to remove any 
finger prints, remaining felt pen marks used to divide up the original sheet of film (other than the 
orientation line), and tape or Super Flab® residue. The film, centered on the scanner bed using a 
cardboard template to ensure film placement reproducibility, was aligned so that the long axis of 
the scanner was parallel to the long axis of the film (see Figure C.1). Due to the asymmetric 
structure of EBT2 film, care was taken to ensure that the film was always scanned with the 50 
μm thick polyester layer facing the glass window on the bed of the scanner. To avoid any large 
change in light intensity as the scanner lamp warmed up, five scans were initially performed in 
the absence of film to ensure a stable light output (Oves 2008). The film was scanned in 
transmission mode using the software Image Acquisition (International Specialty Products, 
Wayne, NJ) and was stored as a 300 dpi, 16-bit, TIFF image. 
 The TIFF images were analyzed using the software ImageJ v1.42p (National Institutes of 
Health, Bethesda, MD). For the monochromatic irradiations, the exposed region of each piece of 
Figure C.1: Epson 1680 Professional flatbed 
scanner. The cardboard template was used to 




film consisted of a 3.0 x 2.5 cm
2 
area centered on the film. For the 4 MV irradiations, the entire 
area of the film was uniformly irradiated and, therefore, a larger ROI (approximately 1.0 x 1.0 
cm
2
) was selected. The mean pixel value for the red channel was obtained for a region of interest 
(ROI) measuring 0.5 x 0.5 cm
2 
centered on the film image. The center of the film corresponded 
to the effective point of measurement for the ion chamber. The red channel pixel values were 
converted into optical density using a logarithmic calibration curve obtained from a NIST 
calibrated TIFFEN Transmission Photographic Step Tablet #2 (see Figure C.2; The Tiffen 
Company, Rochester, NY). For each film, the NOD was calculated by taking the difference 
between the optical density of the exposed film and the average optical density determined from 
the two unexposed pieces of film. The unexposed pieces of film were analyzed in the same way 
as exposed films. 
C.1.4 Film Calibration Curves  
 The results of each calibration curve were consistent with one another at the same energy. 
This indicates an ability of achieving a high level of consistency for each calibration setup. 
Figure C.3(a) shows the NOD versus dose plots for EBT film calibrated at 35 keV and 4 MV. 
Figure C.3(b) shows the NOD versus dose plots for EBT2 film calibrated at 25, 30, and 35 keV 
and 4 MV. The uncertainty in the dose consists of two components: (1) beam output variations 
independent of the storage ring current, and (2) the systematic error associated with the TG-61 
calibration factors. The uncertainty in the measured dose was determined to be within ±5%. 
Figure C.2: NIST calibrated TIFFEN Transmission Photographic 






C.2 Validation of Ion Chamber Dosimetry 
 To validate the use of TG-61 ion chamber dosimetry to estimate the dose rate for cell 
irradiations, dose to water in a PMMA phantom was measured using (1) an ion chamber where 





which was used in MCNP5 Monte Carlo simulations of the irradiation geometry that provided 
Figure C.3: Calibration curves for EBT and EBT2 
films. (a) NOD versus dose for EBT film. The film was 
calibrated at 35 keV (filled squares) and 4 MV (hollow 
squares); (b) NOD versus dose for EBT2 film. The film 
was calibrated at 25 keV (circles), 30 keV (triangles), 
35 keV (filled squares), and 4 MV (hollow squares). 
All sets of data were fitted with the function shown in 




the dose deposition per photon fluence as a function of depth in the phantom. Refer to Brown et 
al. (2012b) for details. 
 Briefly, a cylindrical, air-equivalent ion chamber was used to measure the ionization 
created in a 10 x 10 x 10 cm
3
 PMMA phantom for depths of 0.58 to 7.7 cm and converted to 
dose using TG-61, as discussed in Section 3.2.2.7. The beam fluence was determined using a 
NaI(Tl) scintillation detector (Alpha Spectra, Grand Junction, CO) to make x-ray scattering 







(see Figure C.4). The calculated fluence was used to normalize a MCNP5-calculated 
depth-dose profile for a PMMA phantom, which was compared with the ion chamber measured 
dose.  
 Figure C.5 shows plots of dose to water versus PMMA depth at 35 keV and 25 keV. 
Dose values per 100 mA from ion chamber measurements were compared with the fluence 
normalized-MCNP5 dose calculations (Brown et al. 2012b). The plots show good agreement 
with the intercomparison within approximately 7% and 3% at 25 and 35 keV, respectively, 
validating the use of TG-61 protocol to determine cell dose. 
Figure C.4: Geometry of Compton scattering 





Figure C.5: Dose to water versus PMMA depth. Irradiation energies 
were (a) 35 keV and (b) 25 keV. Ion chamber measurements are 
compared with the product of a MCNP5 calculation and measured 
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